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Abstract
Of the 3.5 million persons infected with chronic HCV in the United States, the African
American population is the largest racial group with chronic HCV. Disparities in access
to care and treatment involve a complex set of individual, interpersonal, socioeconomic,
and environmental factors that influence the course of HCV infection in the African
American population, resulting in poorer outcomes and survival. Drawing upon both the
theory of reasoned action and the theory of planned behavior, this study was conducted to
determine whether the seeking of health care by HCV-positive African Americans and
the responses of health care providers to HCV-positive African Americans had improved
since 2008 following the introduction of new treatment options, as compared to other
HCV-positive racial/ethnic groups, using secondary data analyses with survey datasets
from the National Health and Nutrition Examination Survey, 2005-2012. Using chisquare test of difference and logistic regression analyses, the study did not identify a
statistically significant relationship between health care seeking behavior and responses
from health care providers for HCV-positive African Americans before (2005-2008) and
after (2009-2012) the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups. Given the ongoing development of new and improved
drugs to treat HCV infection, further research might focus on the HCV-infected
population as a whole to ascertain whether differences exist as compared to earlier
therapies before 2013. This study may drive social change within the health care
community by raising awareness of the risks of HCV infection resulting in less provider
bias and the introduction of resources into the African American and underserved
communities that will improve outcomes and reduce barriers to care.
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Chapter 1: Introduction to the Study
Introduction
There are approximately 3.5 million people with chronic hepatitis C virus (HCV)
infection in the United States (Centers for Disease Control and Prevention, 2012a).
African Americans have a two-fold higher prevalence (3.0%) compared to Caucasians
(1.3%) and Hispanics (1.5%; Kemmer & Neff, 2010). In addition, HCV-infected African
Americans are disproportionately affected when it comes to HCV-related morbidity,
mortality, access to care, quality of care, and treatment response. African Americans
have poorer health outcomes, including a two-fold higher rate of liver cancer, a 2- to 3times higher rate of liver cancer-related mortality, and lower rates of survival from liver
transplantation (Layden et al., 2012; Pearlman, 2006). Since 2008, newer treatment
options have been available for HCV infection; prior to 2008, the treatment for HCV
infection had remained the same for 13 years. Although previous researchers have
examined health disparities in HCV-infected African Americans, very little research has
been published concerning this cohort since newer treatment options were made available.
Understanding the association between health disparities in HCV-infected African
Americans since the introduction of newer treatment options could help public health
professionals and healthcare providers develop strategies for eliminating health
disparities affecting HCV-infected African Americans, including earlier prevention
measures employing community-based clinics, providers, and resources for low
socioeconomic communities to promote antistigmatization and better access and
treatment. The most recent data on HCV infection in the U.S. population were collected
by the 2011-2012 National Health and Nutrition Examination Survey (NHANES). The
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research used the NHANES datasets for an 8-year period (2005-2012) to examine the
health care seeking behavior and provider responses of HCV-positive African Americans.
In this chapter, I discuss the current status of HCV infection in the United States
and provide a brief summary of the relation between HCV infection and African
Americans. I also describe the specific goals of the research, the hypotheses tested, and
operational definitions. In addition, I discuss the scope, assumptions, delimitations, and
limitations of the study. Finally, I provide a brief summary of the expected significance
of the results as they relate to advancing knowledge, practice, and social change.
Background
In the United States, HCV is a major cause of chronic liver disease, end-stage
liver disease, and liver cancer (Centers for Disease Control and Prevention, 2012a).
Among persons who acquire HCV, 20% to 25% will naturally clear the virus; the
remaining will not clear the virus and will become chronically infected with HCV
(Centers for Disease Control and Prevention, 2012a). Over the period of the first 20
years, 20% of persons with chronic HCV will develop cirrhosis (permanent scarring of
the liver); one to seven persons with chronic HCV will develop liver cancer yearly
(Centers for Disease Control and Prevention, 2012a; Kanda, Yokosuka, & Omata, 2013).
Major causes of death in the HCV-infected population are end-stage liver disease and
liver cancer; the only therapeutic option is a liver transplant (Layden et al., 2012). Most
persons infected with HCV do not experience symptoms and will only seek medical
attention in the late stages of liver disease when symptoms finally appear.
HCV infection is more prevalent in the African American population than in any
other racial group. Although African Americans represent only 13% of the U.S.
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population, they make up almost one quarter (22%) of all HCV cases (Centers for
Disease Control and Prevention, 2012a). End-stage liver disease from HCV is one of the
leading causes of death for African Americans between the ages of 45 and 64 (Pearlman,
2006). Overall, there is a two-fold higher incidence of HCV-related mortality for African
Americans as compared to non-Hispanic Whites (Saab, Jackson, Nieto, & Francois,
2014). African Americans infected with HCV have poorer health outcomes and lower
rates of survival from liver transplantation (Layden et al., 2012; Pearlman, 2006). When
African Americans infected with HCV are given the current treatment, their rates of
sustained viral response (SVR) and viral clearance are lower compared to Caucasians
(Burton, Passarella, & McGuire, 2012).
The major risk factor for HCV infection is injection drug use. The overall rate of
HCV infection is estimated at between 60% and 90% among injection drug users (IDUs);
in addition, 60% of new HCV cases occur in this cohort (Nelson et al., 2011). African
Americans have a higher prevalence of injection drug use, which contributes to their
higher rate of HCV infection (Amon et al., 2008). Results from the 2011 National
Survey on Drug Use and Health found that reported illicit drug use within the past month
was highest for the following groups: (a) African Americans (10%), (b) males (9%), (c)
ages 18-25 (23.8%), (d) those who did not graduate from high school (11.1%), and (e)
unemployed (17.2%; U.S. Department of Health and Human Services, 2012). Studies
have found that African American injection drug users have a greater burden of injectionrelated health issues, including higher HCV rates, as compared to non-Hispanic White
injection drug users (Jordan et al., 2013; Korthuis et al., 2012). Although HCV treatment
can be effective among injection drug users, assessment and uptake remain low (Grebely
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et al., 2009). Injection drug users may be wrought with actual or perceived
stigmatization that keeps them from seeking care, including HCV testing (Jordan et al.,
2013). In addition to the issue of injection drug use, African Americans are
disproportionately affected by socioeconomic factors, lack of adequate health insurance,
and high treatment costs, which affect their health and contribute to disparities in health
care access and treatment, as demonstrated in their poorer outcomes and survival of HCV
infection (Melia at al., 2011).
By 2019, the direct medical costs of treating persons with chronic HCV infection
are projected to exceed $10.7 billion; the societal cost from premature death is estimated
at $54.2 billion (Wong, McQuillan, McHutchison, & Poynard, 2000). From the years
2008 to 2011, pivotal clinical trials introducing novel direct-acting antivirals (DAAs) for
the treatment of HCV infection were made available in the United States, followed by the
Food and Drug Administration’s approval of two new DAAs, telaprevir and boceprevir,
in May 2011. Prior to 2008, the treatment for HCV infection had remained unchanged
for 13 years. Newer treatment options have demonstrated improved response rates for
African Americans (Burton et al., 2012). As a result, it is even more imperative that the
health disparities impeding the care and treatment of HCV-infected African Americans
are overcome with earlier intervention to reduce costs and improve outcomes. Because
HCV is a major health problem in the United States and significant health disparities
affect HCV-infected African Americans, it is important to determine whether the
introduction of newer treatment options with better response rates has improved both
health care seeking behavior and provider responses for this population.
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Problem Statement
There are disparities in access to care and treatment affecting the African
American population that are demonstrated in this population’s outcomes and survival of
hepatitis C virus (HCV) infection (Artinyan et al., 2010; Davila & El-Serag, 2006; Jan et
al., 2012). Rates of HCV infection and HCV-related mortality are twice as high for
African Americans as compared to non-Hispanic Whites (Saab et al., 2014). Disparities
also exist for HCV-infected African Americans due to disproportionately low
socioeconomic status indicators (e.g., income and education); greater risk for and burden
of disease; and insufficient access to, delivery of, and quality of health care (Artinyan et
al., 2010; Davila & El-Serag, 2006; Sloane, Chen, & Howell, 2006; Tohme, Xing, Liao,
& Holmberg, 2013). Beginning in 2008, pivotal clinical trials introducing novel directacting antivirals (DAAs) for the treatment of HCV infection were made available in the
United States; in May 2011, the Food and Drug Administration approved two new DAAs,
telaprevir and boceprevir. Prior to 2008, the standard of care for HCV infection had
remained the same for 13 years. As a result, no previous studies have examined the
health care seeking behavior and provider responses associated with HCV-positive
African Americans since the introduction of newer treatment options.
Purpose of the Study
In this quantitative study, I used data from the 2005-2012 NHANES datasets to
determine whether the seeking of health care by African Americans who are HCVpositive, and the offering of treatment by providers to African Americans who are HCVpositive, had improved since 2008 following the introduction of new treatment options.
The independent variable was HCV-positive persons who completed the 2005-2012
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NHANES Hepatitis C Follow-Up Questionnaire (HCQ). The dependent variables were
the health care seeking behavior of HCV-positive persons and provider responses to
HCV-positive persons and were represented by 10 questions from the NHANES
Hepatitis C Follow-Up Questionnaire (HCQ).
Research Questions and Hypotheses
Two research questions guided this research. The questions, including null and
alternative hypotheses, were as follows:
Research Question 1
Has the seeking of health care, as defined by self-report HCQ responses, by HCVpositive African Americans improved since 2008 following the introduction of new
treatment options as compared to other HCV-positive racial/ethnic groups?
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ
responses, by HCV-positive African Americans has not improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans has improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Research Question 2
Has the response from health care providers, as defined by self-report HCQ
responses, to HCV-positive African Americans improved since 2008 following the
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introduction of new treatment options as compared to other HCV-positive racial/ethnic
groups?
Null hypothesis (H02): The response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans has not improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
Alternative hypothesis (Ha2): The response from health care providers, as defined
by self-report HCQ responses, to HCV-positive African Americans has improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
Theoretical Framework for the Study
The theory of reasoned action (TRA) was developed by Ajzen and Fishbein in
1980, and evolved out of the expectancy value models in an attempt to understand the
incongruity between attitude and behavior (Ajzen, 1991). The TRA indicates that the
intention to perform a behavior is a function of attitudes toward engaging in the behavior
and perceived normative pressure to perform the behavior (Glanz, Rimer, & Viswanath,
2008). Therefore, performing a behavior is a function of a person’s intentions, which
represents a combination of the person’s own attitudes toward the behavior and his or her
subjective norms (Linke, Robinson, & Pekmezi, 2013). By understanding a person’s
attitude toward a health behavior (including the consequences of the health behavior),
and what the person believes other people, especially influential people, would expect
him or her to do, one can have an impact on whether the individual will seek medical care.
It has been demonstrated that TRA is most useful in predicting behaviors under
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volitional or perceived control; however, as discovered later on by Azjen and Fishbein,
some behaviors are not entirely within an individual’s control (Azjen, 1991; Linke et al.,
2013). In an attempt to better predict health behaviors, the theory of planned behavior
(TPB) was also incorporated into the theoretical framework (Ajzen, 1991). The TPB
adds a construct called perceived behavioral control, which is defined as individuals’
perceptions of their ability to perform a given behavior (Ajzen, 1991). This theory
introduces an individual’s control beliefs, which are defined as (a) the presence or
absence of perceived facilitators and barriers associated with a given behavior and (b) the
impact of these facilitators and barriers (Linke et al., 2013).
TRA and TPB were applied in the effort to determine health-seeking behaviors
and influence behavioral change in the African American population infected with
hepatitis C with regard to medical care access, follow-up, and treatment. In this research,
I attempted to determine whether the influence of newer drug treatments had improved
health-seeking behavior and provider responses for African Americans infected with
hepatitis C. In its focus on real-world application, this study may serve to promote action
on attitudes about HCV risk reduction, response to social norms (in the African American
community), and intentions to change risky behaviors (e.g., intravenous drug use, risky
sex practices) (Kiragu & Pulerwitz, 1999).
Nature of the Study
This study was a quantitative assessment that used secondary data from the
National Health and Nutrition Examination Survey (NHANES) and Hepatitis C FollowUp Questionnaire (HCQ) for the following time periods: (a) 2005-2008 (before the
introduction of new treatment options) and (b) 2009-2012 (during and after the
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introduction of new treatment options). Both surveys used a Likert-type format and
collected relevant information from respondents that included sociodemographic
information, health insurance status, drug use, health care seeking behavior, and provider
responses. Using the NHANES datasets, I conducted analyses of categorical variables
that included age, gender, race, education, poverty index, health insurance status, and
history of illegal injection drug use to provide descriptive statistics. The independent
variable consisted of all participants who tested positive for hepatitis C and completed the
HCQ. The dependent variables, health care seeking behavior and provider responses,
were assessed through a total of 10 HCQ questions. Using the 2005-2012 HCQ datasets, I
conducted statistical analyses of 10 survey questions using chi-square for frequencies and
Fisher’s exact where applicable (e.g., small cell sizes) to examine all participants by
racial/ethnic group in two time periods: 2005-2008 and 2009-2012 (Field, 2013).
The study population was composed of 2005-2012 NHANES survey participants
6 years of age or older who tested positive for hepatitis C (anti-HCV) and who also
completed a Hepatitis C Follow-Up Questionnaire (HCQ) over the telephone. All four
NHANES 2-year datasets from 2005 to 2012 provided all the relevant questionnaires and
variables necessary to conduct the research. The NHANES collates nationally
representative data on the health and nutritional status of the noninstitutionalized civilian
population of the United States (Centers for Disease Control and Prevention, 2013a).
NHANES uses a stratified and multistage probability sampling design and collects
information from persons using standardized household interviews, physical
examinations, and testing of biologic samples; the data are published in 2-year cycles
(Ditah et al., 2014). Data were collected according to NHANES procedures (Protocol
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#2005-06, Protocol #2011-17), which were approved by the Ethics Review Board of the
National Center for Health Statistics Research (Centers for Disease Control and
Prevention, 2012b). I describe the survey population and data collection methods in
detail in Chapter 3.
Operational Definitions
The following terms and phrases are defined as used in the present study.
Hepatitis C antibody positive confirmed: hepatitis C antibody (anti-HCV) positive
is a value that is calculated on all examinees 6 years or older by a serum specimen with
laboratory testing as follows: Samples testing positive for anti-HCV by the screening test
are tested in the confirmatory RIBA assay for antibody to Hepatitis C virus; samples with
a positive RIBA result are reported as confirmed positive for antibody to HCV (Centers
for Disease Control and Prevention, 2012c). Samples with a negative RIBA result are
reported as negative for antibody to HCV. Samples with indeterminate RIBA results are
tested for HCV-RNA (Centers for Disease Control and Prevention, 2012d).
HCV-positive: This term is defined as applying to those NHANES participants
who tested positive for antibody to HCV (anti-HCV), as well as to participants with
indeterminate anti-HCV results who tested positive for HCV-RNA for survey years
2005-2012 (Denniston, Klevens, McQuillan, & Jiles, 2012).
Assumptions
Assumptions are factors that can potentially influence a study, but for which no
hard data exist (Simon, 2011). The assumptions, although not controlled for, are
considered probably true and necessary; if they were absent, the study would become
irrelevant (Simon, 2011).
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This study was based on the following assumptions:
•

All study participants met NHANES eligibility.

•

All NHANES surveys and questionnaires were administered according to the
survey protocol.

•

All study participants answered the NHANES survey truthfully.

•

All laboratory samples were collected, handled, and analyzed according to
laboratory protocols.

•

All data downloaded from the CDC website were current and correct and have
been handled and stored according to accepted data-management practices.
Scope and Delimitations

The scope of this study was the 2005-2012 NHANES study populations; the
sample population used for the study was defined as consisting of individuals 6 years of
age or older who were anti-HCV positive and completed the Hepatitis C Follow-Up
Questionnaire (HCQ). The NHANES total population for the time period 2005-2012
equaled 40,790 persons. For this same time period, a total of 394 (1.3%) out of 29,752
serum samples tested positive for anti-HCV antibody (Centers for Disease Control and
Prevention, 2013a). One hundred thirty-two (33%) of the 394 anti-HCV positive
individuals completed the HCQ. Data for the 2005-2012 NHANES surveys were
collected from January 2005 through December 2012. Although NHANES provides a
representative sample of the U.S. population, the National Center for Health Statistics
analytic guidelines recommend combining HCQ data with other cycles when doing
analysis and indicate that data from HCQs should not be used with sample weights to
make national estimates due to small sample size and a response rate below 50% (Centers
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for Disease Control and Prevention, 2012c). The study was bound by the characteristics
of the 2005-2012 NHANES study populations. The study did not analyze respondents
who refused to complete the HCQ phone interview after being notified of an HCV
positive test result, or respondents for whom data were missing.
Limitations
The NHANES variables were derived from self-report of the respondent; as a
result, the potential exists for the variables to be affected by recall bias or
misunderstanding of the question (Centers for Disease Control and Prevention, 2012e).
The HCQ has a nonresponse bias that needs to be assessed and reported, and any
information on reasons for missing data should be presented (Perlin, 2003). The sample
of HCV-positive participants was small and cannot be generalized to the U.S. population.
The independent variable, serum anti-HCV antibody level, was subject to measurement
variation, as well as to examiner effects (Centers for Disease Control and Prevention,
2012e). To address these limitations, public health and scientific communities reviewed
the NHANES protocols (Centers for Disease Control and Prevention, 2013b). Field staff
interviewers are involved in comprehensive training and retraining on an annual basis;
quality control measures are also implemented with interviewer monitoring, as well as
data collection processes and systems (Centers for Disease Control and Prevention,
2013b). Another analytic limitation of the NHANES sample is that it was selected from a
relatively small number of sampling units (PSUs) or counties, which may introduce a
higher level of uncertainty in the annual estimates (Perlin, 2003). The computation of 2year datasets is preferred to decrease variability in annual estimates.
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Significance of the Study
The aim of this research was to determine whether health care seeking behavior
and provider responses for HCV-positive African Americans have improved since 2008
with the introduction of newer treatment options as compared to other HCV-positive
racial/ethnic groups. Given that the African American population has the highest
prevalence of HCV infection in the United States, it is important to understand the health
disparities that make it difficult to identify and prevent transmission of this deadly virus
within African American communities. There are gaps that need further investigation in
order to enable understanding of the “access to care” element for the African American
population; in other words, more information is needed to answer the following
questions: “What percentage of the population that has been diagnosed with HCV has
medical insurance and is seeking health care for HCV?” “Where is the misstep when it
comes to the care of this population?” “Is it with the providers’ responses and treatment
decisions, or is it with the population who, although they have medical insurance, are not
seeking medical attention; or, on the other hand, do not have medical insurance and are
not seeking medical attention?”
HCV infection remains a critical public health challenge in the African American
population. African Americans are most at risk of infection and transmission due to
illegal injection drug use behavior, in addition to worse health outcomes including
increased morbidity and mortality. In order to reduce overall HCV prevalence at the
population level, promotion, education, and intervention strategies need to be based in
African American communities. The findings add to the body of research on health
inequities with minority and underserved populations, including populations with lower
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socioeconomic status in general. Positive social change may occur in the way of
reinforcing awareness of the risks of HCV infection, reducing provider bias, and
introducing resources into the African American communities to allow better access to
care for this population, improving outcomes and removing barriers to care. The findings
may introduce implications for future research to assess why African Americans do not
access health care and potential solutions to those barriers, perhaps with a communitybased participatory approach formed by an integrated group of health care providers,
community members, patients, families, and other key stakeholders.
Summary
HCV infection is a serious health problem within the African American
community. There are disparities with access to care and treatment for the HCV-positive
African American population that result in poorer morbidity and mortality (Artinyan et
al., 2010; Davila & El-Serag, 2006; Jan et al., 2012). Disparities also exist for HCVinfected African Americans due to disproportionately lower socioeconomic status, greater
risk for and burden of disease, and insufficient access to, delivery of, and quality of
health care (Artinyan et al., 2010; Davila & El-Serag, 2006; Sloane, Chen, & Howell,
2006; Tohme, Xing, Liao, & Holmberg, 2013). Newer treatment options have improved
cure rates for all HCV-infected populations. This study addressed the following
question: Has the health care seeking behavior and provider responses for HCV-positive
African Americans improved since 2008 with the introduction of newer treatment options
as compared to other HCV-positive racial/ethnic groups? The study’s findings may guide
public health policies and health care providers in targeting groups that are most at risk.
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In Chapter 2, I provide background information on the results of previous
research related to HCV infection, based on an extensive literature search. I examine the
role of HCV infection in the United States, and its epidemiology, risk factors, morbidity,
mortality, sociodemographic factors, economic burden, and treatment. I also specifically
examine HCV infection in the African American population, including epidemiology,
risk factors, clinical features, and access to care and treatment.
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Chapter 2: Literature Review
Introduction
There are disparities in access to medical care and treatment for the African
American population that are demonstrated in their outcomes and survival of hepatitis C
virus (HCV) infection (Artinyan et al., 2010; Davila & El-Serag, 2006; Jan et al., 2012).
The rates of HCV infection and HCV-related mortality are twice as high for African
Americans as compared to non-Hispanic Whites (Saab et al., 2014). Disparities also exist
for HCV-infected African Americans due to disproportionately lower socioeconomic
status indicators (e.g., income and education); greater risk for and burden of disease; and
insufficient access to, delivery of, and quality of health care (Artinyan et al., 2010; Davila
& El-Serag, 2006; Sloane et al., 2006; Tohme, Xing, Liao, & Holmberg, 2013).
In 2008, pivotal clinical trials introducing novel direct-acting antivirals (DAAs)
for the treatment of HCV infection were made available in the United States, followed by
the Food and Drug Administration’s approval in 2011 of two new DAAs, telaprevir and
boceprevir. Prior to 2008, the treatment for HCV infection had remained the same for 13
years. The new treatment regimens using DAAs with pegylated interferon and ribavirin
have improved sustained viral response (SVR) rates for the HCV-infected African
American population as compared to the previous non-DAA therapies (50-62% versus
19-21%, respectively; Burton et al., 2012). The purpose of this research was to determine
whether the seeking of health care by HCV-positive African Americans, and the
responses from health care providers to HCV-positive African Americans, had improved
since 2008 following the introduction of new treatment options, as compared to other
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HCV-positive racial/ethnic groups, using survey datasets from the National Health and
Nutrition Examination Survey (NHANES).
This literature review addresses HCV infection in the United States, and its
epidemiology, risk factors, morbidity, mortality, sociodemographic factors, economic
burden, and treatment. This review also specifically addresses HCV infection in the
African American population, including epidemiology, risk factors, clinical features, and
access to care and treatment.
Literature Search Strategy
Within the Walden University Library, I used the following research databases to
conduct this literature review: MEDLINE, PubMed, ScienceDirect, Cochrane Reviews,
and Academic Search Complete. Within the UCLA Library, I used the ProQuest
research database to conduct this literature review. Search terms included African
American, hepatitis C, United States, access to care, disparities, epidemiology, race, risk
factors, treatment, socioeconomic status, injection drug use, and health seeking behavior.
I did not limit the search by year of publication and searched all databases up to the
present date. In addition, I located additional governmental and medical information
resources by using Google.
I identified a total of 175 publications from the years 1990 to 2015 for review, and
I included all publications based on their relevance to the present study. The articles
selected were grouped into the following categories as they related to hepatitis C in the
United States: epidemiology, liver cancer/transplant, burden and/or cost, treatment
response and/or uptake, injection drug use, African American and/or race, and health
seeking behavior. The majority of the cited references were published in peer-reviewed,
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scientific journals. Almost all of the selected studies took place in the United States, with
the exception of a few international review articles that included the United States.
Theoretical Framework
The theory of reasoned action (TRA) and theory of planned behavior (TPB) were
developed in an effort to explain why people behave in the way they do and to understand
the decisions and actions that make a person change an unhealthy behavior to a healthier
behavior (Lezin, 2015). Both are useful to those wishing to assess and better understand
health care seeking behaviors, as well as to influence behavioral change in the African
American population infected with HCV with regard to medical care access, follow-up,
and treatment. Through this research, I attempted to assess and understand whether the
influence of newer drug treatments had improved access to care for African Americans
infected with HCV. Further, I hoped to form a bridge from this research to real-world
application by promoting action concerning attitudes about HCV risk reduction, response
to social norms (in the African American community), and intentions to change risky
behaviors (e.g., intravenous drug use, risky sex practices; Kiragu & Pulerwitz, 1999).
Theory of Reasoned Action
TRA centers on a person’s intention to behave in a certain way. An intention is a
“plan or a likelihood that someone will behave in a particular way in specific situations,”
whether this happens or not (Glanz et al., 2008, p. xx). For example, a person infected
with HCV may be thinking about seeking follow-up care and/or treatment, but may or
may not actually follow through on that intent. To understand behavioral intent, TRA
may be used to examine the person’s (or population’s) attitudes toward the behavior, as
well as subjective norms (Linke et al., 2013). Subjective norms are influenced by how a
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person believes those around him or her will think about the behavior in question; these
people are generally influential in some way and may include parents, friends, partners,
or a pastor. Jordan and colleagues (2013) explored the perceptions of drug users and
found that leveraging support from peers may be a valuable way to engage injection drug
users in HCV care.
As discussed previously, people’s attitudes and norms decide their intentions,
which, in turn, are the main drivers of behavior (Lezin, 2015). People’s attitudes toward
a particular behavior are influenced by their beliefs about the outcome of the behavior
and their evaluation of the potential outcome. Mehta and colleagues (2008) found that
the majority of HCV-infected injection drug users reported that a belief that treatment
would not cure them. African American injection drug users from another study
perceived treatment as unimportant because they lacked symptoms, providers minimized
the severity of the disease, or providers did not recommend treatment (Jordan et al.,
2013). The more there is an understanding of a person’s or population’s attitudes and
norms, the greater the ability to introduce more precise and successful interventions.
Theory of Planned Behavior
To enhance the prediction process concerning a person’s health behaviors, TPB
can also be incorporated into research. TPB brings with it a paradigm called perceived
behavioral control, which is defined as the extent to which people believe that they do or
do not possess the necessary skills and resources to overcome any difficulties in engaging
in a behavior (Ajzen, 1991). TPB involves consideration of volitional control as a
variable. Volitional control, by definition, requires having the resources, opportunity,
and support available to perform a specific behavior (Ajzen, 1991). In the published
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literature, several studies have demonstrated that health disparities prevent these elements
from being available for African Americans infected with HCV and that therefore, this
population lacks the ability or behavior to seek and receive adequate and proper care
(Artinyan et al., 2010; Backus et al., 2014; Ditah et al., 2014; Jan et al., 2012; Jordan et
al., 2013; Mathur et al., 2010).
Hepatitis C Virus Infection in the United States
The hepatitis C virus (HCV) was discovered by researchers in 1989; prior to that
time, it was known as non-A, non-B hepatitis (Lindenbach & Rice, 2005). HCV consists
of a 9,600 nucleotide genome-single polyprotein; there are seven genotypes that predict
treatment response, with genotype 1 (harder to treat) accounting for approximately 70%
of infections in the United States (Ward, 2014). HCV is the most common blood-borne
infection in the United States (Ditah et al., 2014). Diagnosis of HCV is confirmed by two
tests: (a) anti-HCV antibody test and (b) HCV RNA test. If both tests are positive, a
person is HCV infected and requires a medical evaluation for active infection and liver
disease (Centers for Disease Control and Prevention, 2015a; Gretch, 1997).
Prevalence of HCV infection in the United States has been estimated from 2.7 to
3.5 million persons, which equals 1.0-1.4% of the population (Denniston et al., 2014;
Ditah et al., 2014). Since the introduction of effective screening of blood product donors
in the 1990s, the incidence of new infections has declined dramatically; in 2012, only
21,870 persons were estimated to have acquired new HCV infections (Centers for
Disease Control and Prevention, 2015b). Among all persons who initially acquire HCV,
20-25% will clear the virus naturally and 75-80% will develop chronic HCV (Centers for
Disease Control and Prevention, 2012a). Within the first 20 years, 20% of persons with
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chronic HCV will develop cirrhosis (permanent scarring of the liver); one to seven will
develop liver cancer yearly (Centers for Disease Control and Prevention, 2012a; Kanda et
al., 2013).
Risk Factors
The risk factors for acquiring HCV in the United States include injection drug use,
sexual transmission, perinatal transmission, occupational exposures among health
workers, incarceration, intranasal drug use, tattooing, receipt of solid organ
transplantation, and other percutaneous exposures, including a history of receiving a
blood product transfusion prior to 1992, hemophilia with receipt of factor concentrates
made before 1987, and hemodialysis (U.S. Preventive Services Task Force, 2014). In
addition, adults born between 1945 and 1965 have been identified as a high-risk group
because they are more likely to have received blood transfusions before 1992 or to have a
history of other risk factors for exposure decades earlier (U.S. Preventive Services Task
Force, 2014). In at least 21% of HCV-positive individuals, no risk factors for infection
are identified (U.S. Preventive Services Task Force, 2014).
Injection drug use. Injection drug use is the most prevalent risk behavior and
primary driver for HCV virus transmission (Centers for Disease Control and Prevention,
2015b). The mortality rate for injection drug users (IDUs) who are infected with HCV is
1 to 2 per 100 person years (Degenhardt, Hall, & Warner-Smith, 2006). Researchers
have found that IDUs account for 60% of newly diagnosed HCV cases (Jordan et al.,
2013; Nelson et al., 2011). Prevalence of HCV among IDUs is 65% and greater than
80% among long-term IDUs (Hagan et al., 2008). A global systematic review of over
1,100 data sources found that approximately 73% of all IDUs in the United States carry
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chronic HCV infection (Nelson et al., 2011). In a meta-analysis of HCV-infected IDUs,
researchers found that the 20-year cirrhosis prevalence was 15% (John-Baptiste et al.,
2010). Researchers have identified the following sociodemographic characteristics to be
associated with IDUs: a lack of health insurance, transportation problems, insufficient
disposable income to cover health care costs, residing in low medical coverage areas, an
education level of high school or less, low income level, homelessness, and
unemployment (Oche, 2014). In addition, researchers have found that IDUs who engage
in syringe/needle sharing behavior have lower educational attainment (Korthuis et al.,
2012). Although HCV treatment can be effective among IDUs, assessment and uptake
remain low (Grebely et al., 2009). Injection drug users may be wrought with experiences
of actual or perceived stigmatization that keep them from seeking care, including HCV
testing (Jordan et al., 2013). Researchers have found that once diagnosed, many IDUs do
not receive clear messages about their HCV infection and the follow-up needed, which
has also resulted in mistrust of health care providers (Jordan et al., 2013).
Sexual transmission. Although sexual transmission of HCV in the general
population remains controversial, there is evidence that HCV transmission occurs
through sexual contact, especially among HIV-positive men who have sex with men
(MSM; Bradshaw, Matthews, & Danta, 2013; Tohme & Holmberg, 2010). Heterosexual
transmission of HCV is estimated to occur at a rate of 0-0.6% per year (Bradshaw et al.,
2013). Researchers have found evidence suggesting that there is no increased risk of
sexual transmission of HCV among heterosexual couples in regular relationships (Tohme
& Holmberg, 2010). On the contrary, a heterosexual person who has multiple sexual
partners has a 2- to 3-fold risk of acquiring HCV infection through sexual transmission
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(Tohme & Holmberg, 2010). Women who are HIV positive or have other sexually
transmitted diseases (STDs) have up to a 4-fold risk of acquiring HCV infection (Tohme
& Holmberg, 2010). The risk is greatest for sexual contact between HIV-positive MSM
(aOR 4.1-5.7), and this risk increases with high-risk sexual behavior and the presence of
genital ulcerative disease (Tohme & Holmberg, 2010).
Perinatal transmission. Chronic HCV infection is the most common form in
pregnant women; acute hepatitis C is very rare during pregnancy (Floreani, 2013).
Chronic HCV infection does not have an adverse effect on either the course of the
pregnancy or the newborn infant’s birth weight; conversely, pregnancy does not induce a
negative impact on a woman’s HCV infection as well (Floreani, 2013). The overall rate
of mother-to-child transmission is 3 to 5%, with the most important risk factors for
vertical transmission including high viral load, HIV coinfection, and invasive procedures
(Floreani, 2013). Viral clearance prior to pregnancy is the goal to reduce vertical
transmission of HCV (Floreani, 2013).
Occupational exposures among health workers. For workers who are exposed,
there is currently no recommended prophylaxis for HCV (Zingman, 2013). The risk of
transmission of HCV from an occupational exposure of needlestick is 1.8% (Zingman,
2013). The risk of transmission from HCV from a single mucous membrane exposure is
negligible (Zingman, 2013).
Incarceration. Approximately 2.2 million people in the United States are
incarcerated, and up to 1 in 3 carries HCV infection (Centers for Disease Control and
Prevention, 2014a). The prevalence of chronic HCV infection among prison inmates
ranges as high as 12% to 35% (Centers for Disease Control and Prevention, 2014a).
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HCV infection in this setting is primarily associated with a history of injection drug use.
Transmission in this setting may result from sharing equipment used for injecting drugs,
tattooing, and piercing with other people who are already infected; sexual transmission is
a component as well (Centers for Disease Control and Prevention, 2014a).
Intranasal drug use. Researchers have demonstrated that blood and HCV RNA
are present in nasal secretions and drug-sniffing devices of HCV-infected intranasal drug
users (Aaron et al., 2008). In addition, researchers have suggested that with episodes of
active drug sniffing, HCV will be present with greater frequency and quantity, which
may exacerbate discharge of nasal fluids and blood (Aaron et al., 2008). Little is known
about the quantity of virus required for transmission, but researchers have demonstrated
that HCV can remain viable on environmental surfaces for up to 16 hours (Krawczynski
et al., 2003).
Tattooing. Researchers who conducted a systematic review of the literature over
an 18-year period (1994-2011) found no definitive evidence of transmission of HCV
infection when sterile equipment or professional tattoo parlors were used (Tohme &
Holmberg, 2012). They did find that the risk of HCV transmission was 2- to 3.5-fold
higher when tattoos were applied in nonprofessional settings including prisons or by
friends (Tohme & Holmberg, 2012).
Solid organ transplant recipient. HCV infection is the leading indication for
liver transplantation worldwide (Levitsky et al., 2013). Among kidney transplant
recipients, 10-year survival is approximately 15% lower in HCV-positive compared to
HCV-negative individuals (Levitsky et al., 2013). Other organ transplants that were
examined either have no long-term data (heart, small bowel, and pancreas) or have shown
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no difference in survival between HCV-positive versus HCV-negative recipients (lung;
Levitsky et al., 2013).
Percutaneous exposures. Due to the implementation of blood product screening
in the early 1990s, the prevalence of percutaneous exposures has greatly diminished.
Although HCV infection is an independent risk factor for mortality in hemodialysis
patients, researchers found the prevalence in hemodialysis units to be 14% and a
seroconversion rate of 2.5% per 100 patient-years (Fissell et al., 2004).
Due to donor selection and testing improvements, the blood supply in the United
States has become immensely safer (Zou, Stramer, & Dodd, 2012). Researchers who
examined donor risk found the HCV incidence rate among repeat donors to be in the
range of 2.16 and 2.98 per 100,000 person-years; the residual risk of HCV virus among
all allogeneic donations was found to be below 1 per 1 million donations (Zou et al.,
2012).
A majority of the cases of HCV infection in persons with hemophilia are
presumed to result from blood transfusions before sensitive screening tests were
introduced in 1992 (Orman & Fried, 2012). Persons with hemophilia acquire HCV
infection at a lower mean age of 9-10 years relative to other groups at risk (Orman &
Fried, 2012). Researchers have reported the prevalence of HCV infection among persons
with sickle-cell disease ranging from 10-20% and among persons with thalassemia at
35% (Orman & Fried, 2012).
Born during 1945-1965. Seventy-five percent of all persons living with HCV
infection and 75% of HCV-associated deaths are attributed to those who were born
during the years 1945 to 1965 (Centers for Disease Control and Prevention, 2015a). The
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prevalence of HCV antibodies in this cohort is approximately 3%, which is 5 times
higher than in other age cohorts (Centers for Disease Control and Prevention, 2015a). As
a result, the Centers for Disease Control and Prevention (2015a) have added the birth
cohort of 1945-1965 to the HCV one-time screening recommendations.
Morbidity and Mortality
HCV is the cause of death or contributing cause of death in approximately 15,000
people per year with more than 70% of deaths in people ages 45 to 64 years old (Centers
for Disease Control and Prevention, 2015a). Since 2007, mortality among HCV-infected
persons continues to exceed deaths from HIV/AIDS in the United States (Centers for
Disease Control and Prevention, 2015a). HCV-infected individuals have mortality rates
up to 3 times higher than those in the general population; in addition, they carry an 8- to
12-year reduction in overall life expectancy (Jacobson, Cacoub, Dal Maso, Harrison, &
Younossi, 2010). Major factors associated with an increased risk of death include
chronic liver disease, co-infection with hepatitis B or HIV, alcohol-related conditions,
and minority status (Centers for Disease Control and Prevention, 2015a). End-stage liver
disease and hepatocellular carcinoma are significant causes of death in this population,
with liver transplantation as the only therapeutic option for many of these patients
(Klevens, Hu, Jiles, & Holmberg, 2012; Layden et al., 2012). In 2011, chronic liver
disease, including cirrhosis, was the 12th leading cause of death in the United States, and
viral hepatitis-associated death rates were highest among persons infected with HCV
(Centers for Disease Control and Prevention, 2015a). For those who do not succumb to
cirrhosis, this disease is still wrought with other physical and psychological
manifestations which can include fatigue, vasculitis, arthralgias, neuropathy,
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lymphoproliferative malignancies, insulin resistance, type 2 diabetes, depression, and
cognitive impairment (Jacobson et al., 2010). These extrahepatic manifestations have
contributed to approximately 15% of all HCV-related hospitalizations (Moorman, 2013).
Liver transplantation. HCV infection is the leading indication for liver
transplantation. Post-transplantation HCV recurrence is universal and the rate is
accelerated in the new graft compared to pre-transplantation (Levitsky et al., 2013). Posttransplantation recipients demonstrate a recurrence of HCV infection within the first 5
years (Levitsky et al., 2009). Overall 5-year patient survival is 65%, and 5-year graft
survival is 60% in HCV-infected recipients (Levitsky et al., 2009). With the onset of
recurrent HCV cirrhosis comes a 50% incidence of liver decompensation within one year,
which results in a 1- and 4-year patient survival of only 66% and 33%, respectively
(Brown, 2005).
Sociodemographic Characteristics
There are sociodemographic disparities that exist with the HCV infected
population. Researchers examined the National Health and Nutrition Examination
Survey (NHANES) data over an 8-year period (2003-2010) and found that almost onehalf of chronic HCV infected persons were between the ages of 40-59 years, and 64%
were male (Denniston et al., 2014). In addition, if a person had less than a high school
education/GED (< 12th grade), they were twice as likely to have chronic HCV infection
(OR 2.0, 1.2-3.3); if a person had a family income less than two times the poverty level
(equals @ $22,000-52,000 based on household size), they were almost four times as
likely to have chronic HCV infection (OR 3.7, 2.6-5.3; Denniston et al., 2014). On the
contrary, using the same data, researchers found the percentage of current, unresolved
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HCV infection was lowest among those with a college education (57.3%; Liu, Holmberg,
Kamili, & Xu, 2014).
Researchers who examined survival of patients with hepatocellular carcinoma
found that lower income patients continue to have the worst survival as compared to
middle- and high-income patients (Artinyan et al., 2010). Inconsistencies in access to
appropriate care as well as differences in underlying disease are thought to be
contributors (Artinyan et al., 2010). Researchers who examined liver cirrhosis using the
NHANES data over a 12-year period (1999-2010) found the prevalence to be higher in
those living below the poverty level, and those with less than a high school education
(Scaglione et al., 2014). The goals of HCV infection as a major public health challenge
include increasing both the proportion of persons who get tested, and the proportion of
persons who test positive receiving the appropriate referral to care and treatment (Centers
for Disease Control and Prevention, 2015a).
Economic Burden
The excessive burden of high treatment costs for managing HCV and its sequelae
not only impacts the patient, but also impacts private and government health care
agencies (Jacobson et al, 2010). Progressive liver disease and its associated health care
costs can be avoided with early diagnosis and treatment of HCV infection. Researchers
have found that direct healthcare costs associated with chronic HCV infection increase in
association with the progression of liver disease, and are highest in persons with endstage liver disease (Gordon et al., 2012). By 2019, the direct medical costs of chronic
HCV infection are projected to exceed $10.7 billion along with a societal impact from
premature mortality estimated at $54.2 billion (Wong et al., 2000). Researchers showed
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that birth cohort screening of all patients born between 1945 and 1965 is cost-effective at
a rate of $2,874 per case identified and can add between $15,700 and $35,700 per
quality-adjusted life year (QALY) based on the type of HCV treatment provided (Rein et
al., 2012).
Treatment of HCV Infection
In 2011, the Food and Drug Administration approved two new direct-acting
antivirals (DAAs) against HCV, telaprevir (TVR) and boceprevir (BOC), in combination
with pegylated interferon and ribavirin (U.S. Food and Drug Administration, 2011). In
studies, the triple combination of TVR or BOC plus pegylated interferon and ribavirin
have demonstrated sustained viral response (SVR) rates in treatment-naïve, genotype 1
patients as high as 66% to 69% (Kanda et al., 2013). Overall, SVR rates are lower in
previous relapse, partial response, non-response, and relapse populations (Kanda et al.,
2013). As of 2013, there is now a total of six second generation DAAs being used (alone
or in combination) for the treatment of HCV infection (U.S. Food and Drug
Administration, 2014). In studies, high rates of SVR (89%-90%) have been
demonstrated in treatment-naïve patients with second generation DAAs (Kohli, Shaffer,
Sherman, & Kottilil, 2014).
HCV Infection in African Americans
African Americans account for 22% of persons infected with HCV in the United
States (Fleckenstein, 2004). The prevalence of chronic HCV infection in the African
American population is 2-fold higher than the Hispanic and Caucasian populations (3%
versus 1.3% and 1.5%, respectively; Kemmer & Neff, 2010). Over a 10-year period,
researchers found that African Americans carried the greatest burden of HCV infection;
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during this same time period, there was also a 27.3% increase in the rate of HCV
infection for this population (Centers for Disease Control and Prevention, 2015a; Ditah et
al., 2014). Researchers who examined the epidemiology of HCV infection using the
NHANES datasets between the years 2001 and 2010 found that African Americans had a
1.5- to 2-fold greater risk of having HCV infection versus all other ethnic groups (Ditah
et al., 2014; Denniston et al., 2014). In addition, HCV-infected African Americans are
disproportionately affected when it comes to morbidity, mortality, access to care, quality
of care, and treatment response.
Hepatitis-C related chronic liver disease is a leading cause of death among
African American persons 45 to 64 years of age (Centers for Disease Control and
Prevention, 2012a). Researchers have demonstrated that African Americans have poorer
health outcomes including a two-fold higher rate of liver cancer, a two to three times
higher rate of liver cancer-related mortality, and lower rates of survival from liver
transplantation (Layden et al., 2012; Pearlman, 2006). In addition, this population suffers
from health disparities that lead to inadequate and inappropriate treatment and care.
Researchers have found that risk factors associated with HCV-related liver disease
morbidity and mortality include ethnicity, access to HCV therapy, and a favorable
treatment response (Grebely & Dore, 2011).
Injection Drug Use
African Americans are substantially and persistently overrepresented among
people diagnosed with injection-related health problems, including higher HCV rates as
compared to non-Hispanic White injection drug users (IDUs; Amon et al., 2008).
Between May 2005 and February 2006, the CDC’s National HIV Behavior Surveillance
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System (NHBS) interviewed more than 10,000 IDUs; African Americans made up almost
one-half (47.1%) of those who participated (Centers for Disease Control and Prevention,
2009a). In addition, results showed that during the preceding 12 months, one-third of
African American participants reported sharing syringes or injection equipment (29.1%
and 33.1%, respectively; Centers for Disease Control and Prevention, 2009a). In addition,
31.4% of African American IDUs reported never getting tested for HCV infection in their
lifetime (Centers for Disease Control and Prevention, 2009a). Data on the socioeconomic
status of IDUs in the United States is difficult to find in the current literature.
Researchers surveyed 600 IDUs in New York City and found that African Americans
were less likely to attend a private medical office in the past year; whereas, those with
higher income and health insurance coverage were more likely to attend a private medical
office (Turner, Harripersaud, Crawford, Rivera, & Fuller, 2013). The relationship
between injection drug use and HCV transmission among the African American
population is well established. In four U.S. cities over a 10-year period (1994-2004),
researchers found that although overall trend declined, the prevalence of HCV infection
in the African American IDUs remained unchanged (Amon et al., 2008). These same
researchers also found that HCV antibody positive prevalence increases with age, number
of years injecting, and intensity of injection drug use (Amon et al., 2008).
Socioeconomic Status
Low socioeconomic status and less education are often associated with high risk
behaviors, including injection drug use, and thus, a higher risk of HCV infection (Ditah et
al., 2014). African Americans are at greater risk for HCV infection due to a poorer
socioeconomic status including poverty, lower employment rates and lack of education
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(Estrada, 2005; Fuller et al., 2005; Galea & Vlahov, 2002). In the United States, African
Americans have one of the highest national poverty rates (25.8%); poverty rates of 20%
or higher exist in 43 states for the African American population (Macartney, Bishaw, &
Fontenot, 2013). Even higher poverty rates exist for African Americans in both single
male-headed households (27%), and single female-headed households (40%); this results
in African American children being three times more likely to live in poverty than
Caucasian children (Macartney et al., 2013). Poverty can lead to early school dropout,
loss of self-worth, and the uptake of illegal or socially unacceptable activities, such as
injection drug use, which puts African Americans at risk for HCV infection (Estrada,
2005).
For the age group16 to 24 years old, as compared to all students combined,
African Americans have higher rates of not being enrolled in school, and not earning a
high school diploma (National Center for Education Statistics, 2011). A researcher that
examined the adverse effects from a poor socioeconomic status among the IDU
population found that 64% of African American males had completed less than 12 years
of school (Galea & Vlahov, 2002). Other researchers found that the initiation of injection
drug use was associated with neighborhood level factors including African American
race, lower employment rates, and lower education levels (Fuller et al., 2005).
Clinical Features
Of the 20-25% who spontaneously clear hepatitis C virus from their body, the rate
is lowest among African Americans versus Caucasians and Hispanics (9% versus 27%
and 31%, respectively) (Mir, Stepanova, Afendy, Kugelmas, & Younossi, 2012).
Researchers have discovered that variation in genes involved in the immune response
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may contribute to the ability of an individual to clear the hepatitis C virus (Thomas et al.,
2009). Researchers conducted a genome-wide association study which identified a single
nucleotide polymorphism of the IL28b gene; from this gene, there are three genotypes:
C/C, C/T, and T/T (Ge et al., 2009). Researchers examined these three genotypes and
their influence on natural HCV clearance and found that African Americans carry a
higher frequency of the IL28b T/T genotype, which is more strongly associated with
lower rates of natural clearance of HCV versus the other two genotypes (Thomas et al.,
2009). These findings help to explain some of the variability in spontaneous HCV
clearance with African Americans leaving still yet more to be discovered with
epidemiological, viral, and host factor associations.
Liver cancer. HCV-infected persons are at risk for developing liver cancer after
two or more decades of infection; those at greatest risk have cirrhosis or advanced
fibrosis (de Oliveria Andrade et al., 2009). Persons with HCV-related cirrhosis have a 26% risk of developing liver cancer after two or more decades (de Oliveria Andrade et al.,
2009). There is a 17-fold increased risk of developing liver cancer for HCV-infected
persons compared to HCV-negative persons (de Oliveria Andrade et al., 2009). The 5year overall survival of persons with liver cancer ranges from 6% to 7% (Artinyan et al.,
2010).
Racial inequities in liver cancer outcomes have been observed (Davila & El-Serag,
2006; Sloane et al., 2006). African Americans have higher rates of liver cancer from
HCV infection (Burton et al., 2012). Researchers examined risk factors for liver cancer
in persons with HCV-related cirrhosis and found that “African American race” was
independently associated with the development of liver cancer in this cohort (Sarbah et
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al., 2004). Researchers examined trends in survival of liver cancer over forty years and
discovered that African Americans have the worst survival, compared with all other
ethnic subgroups (HR 1.66, 95% CI, 1.29-2.12, p < .001; Artinyan et al., 2010).
Researchers who examined 3 national registries over a 21-year period found that,
compared to Caucasians, African Americans had an 11% higher mortality risk, and the
lowest 3-year survival from liver cancer (Davila & El-Serag, 2006).
Liver transplant. Researchers examined racial/ethnic disparities in liver
transplant patients and found that the transplant rate for African Americans was
significantly lower versus Caucasians (Mathur, Schaubel, Gong, Guidinger, & Merion,
2010). Other researchers examined the race related differences during the first 2 years
post liver transplantation and found a greater severity of HCV recurrence and fibrosis
progression among African American recipients; in addition, a higher percentage of
severe fibrosis and poorer patient survival was present in the African American
recipient/White donor group (Layden et al., 2012).
Access to Care and Treatment
Disparities with access to care and treatment for the African American population
are demonstrated in their outcomes and survival of HCV infection. Using the NHANES
data from 2003 to 2010, researchers found that African Americans carried the highest
percentage (91.1%) of current, unresolved HCV infections (Liu et al., 2014). In a broad
population-based study using two national databases, researchers examined 40 years of
liver cancer survival trends and found that both lower income patients and African
Americans continued to have the worst survival rates (Artinyan et al., 2010). Other
researchers have shown similar findings in which health outcomes have not been
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identical when it comes to race, with significantly poorer survival in African Americans;
researchers have addressed these disparities by suggesting racial and health biases in the
delivery of appropriate treatment (Davila & El-Serag, 2006; Sloane et al., 2006).
Researchers that examined liver cancer outcomes over a nine-year period in African
Americans versus Caucasians in an inner-city urban setting found that African Americans
were more likely to present with late stage liver disease (cirrhosis), and with a larger
tumor size at time of cancer diagnosis (Jan et al., 2012). This same African American
cohort was also less likely to have private insurance, and a greater prevalence of IDUs
(Jan et al., 2012).
Health-seeking behavior. With the African American population, themes that
have emerged regarding barriers to health seeking behavior include socioeconomic status,
lack of health insurance, language barriers, lack of awareness of the need for care, racism,
discrimination, distrust of the medical establishment, and religion or spirituality
(Cheatham, Barksdale, & Rodgers, 2008; Hewins-Maroney, Schumaker, & Williams,
2005; Rooks, Wiltshire, Elder, Belue, & Gary, 2012). Researchers who examined the
source of information on health care used by African Americans in low-income
households found that informal channels were preferred with over half (53.9%) using
their family physician, and one-third (30.4%) using their family members (Spink & Cole,
2001). Lower socioeconomic status and minority groups are more likely to rely on
interpersonal and non-medical sources for health information, health maintenance and
treatment of illnesses (Rooks et al., 2012; Kontos, Emmons, Puleo, & Viswanath, 2011).
Relying solely on health care provider interactions can be problematic as well since
African Americans often report fewer participatory medical visits due to real or perceived
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barriers of unfair treatment or mistrust (Blanchard, Nayar, & Lurie, 2007; Johnson, Roter,
Powe, & Cooper, 2004). Researchers found that as education level increases, the odds of
seeking health information increases for all racial and ethnic groups including African
Americans (Rooks et al., 2012). Ethnic/racial minority groups with lower education
levels may have disparities from low health literacy. Low health literacy can result in
communication challenges, limited understanding and input on a person’s care, and a
withdrawal from accessing care due to embarrassment and/or masculinity issues (Rooks
et al., 2012).
An examination of the racial differences in HCV treatment eligibility found that
African Americans are 36% less likely than Caucasians to receive treatment for HCV
infection (Melia et al., 2011). In addition, African Americans have co-morbidities that
can impede their eligibility to receive treatment; they suffer from higher rates of
neutropenia, anemia, diabetes, and renal dysfunction (Melia et al., 2011). Overall, this
introduces the paradox of African Americans carrying the greatest burden of HCV, and
yet having lower treatment efficacy due to poorer response rates or ineligibility. Along
with the individual co-morbidities that impact low treatment rates, African Americans are
also disproportionately affected by the lack of adequate health insurance, and high
treatment costs which present barriers to care for this population (Melia et al., 2011).
African Americans infected with HCV have significantly lower rates of SVR
from treatment (Melia et al., 2011; Muir et al., 2004). Part of this is attributed to
evidence linking African Americans to carrying a high rate of IL28B T/T genotype,
which is associated with lower interferon responsiveness resulting in treatment-induced
HCV clearance, versus other genotypes (Thomas et al., 2009). Persons who achieve SVR
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have a clear advantage at histological and clinical levels versus those who do not achieve
SVR (Muir et al., 2011). Prior to the approval and use of DAAs, the treatment of HCV
had not changed for 13 years, so the existing body of knowledge examining HCVinfected African Americans with these new treatment options remains scarce. In all
phase III clinical trials of the first generation DAAs (TVR and BOC) plus peglyated
interferon and ribavirin, African Americans only comprised 10.6% of combined
enrollment (Burton et al., 2012). When this African American cohort was analyzed,
researchers found that SVR rates had vastly improved with the use of DAA therapy (TVR
or BOC plus peglyated interferon and ribavirin) versus the previous non-DAA therapy
(50-62% versus 19-21%, respectively; Burton et al, 2012).
Clinical studies using second generation DAAs are eliminating the use of an
interferon-based regimen, and therefore, removing the reduced treatment effect of the
more prominent IL28B T/T genotype with the African American cohort. Proof of
concept studies have demonstrated that interferon-free, second generation DAA regimens
(with or without ribavirin) are resulting in efficacious outcomes for this difficult to treat
population (Highleyman, 2013; Osinusi, Bon, & Herrmann, 2013).
Summary
In the United States, African Americans are at particularly high risk of HCV
infection. Several researchers have demonstrated that HCV-infected African Americans
suffer from poorer responses to treatment, lower rates of cure, higher incidences of liver
cancer, higher death rates from liver cancer, and poorer survival rates with liver
transplantation. In addition, researchers have demonstrated that there are health
disparities with HCV-infected African Americans as a result of injection drug use, lower
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socioeconomic status, perceived or actual bias with health care, poorer access to care, and
inappropriate treatment. The NHANES datasets have been used extensively to study
hepatitis C infection status in the U.S. population. The addition of the Hepatitis C
Follow-Up Questionnaire (HCQ) in 2001 along with years of testing participants for antiHCV antibody status have made the NHANES datasets very informative and useful. For
this study, I used the NHANES datasets over an 8-year period, 2005-2012, which
included identification of those who are infected with HCV, race, and HCQ self-report
responses, in order that I was able to examine the health care seeking behavior and
provider responses in this cohort during both pre- (2005-2008) and post- (2009-2012)
DAA periods. In Chapter 3, I present the research design and approach used to address
the research questions and hypotheses. Additionally, I discuss the setting and sample of
the study, and describe procedures for sampling, subject recruitment, and data collection.
I also discuss the instrumentation validity and reliability, and operationalization of the
variables. The threats to validity and ethical considerations are also discussed in this
chapter.
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Chapter 3: Research Method
Introduction
In the United States, approximately 3.5 million persons carry chronic HCV
infection, with African Americans carrying a disproportionately large burden of this
disease (Centers for Disease Control and Prevention, 2012a). African Americans (3%)
carry a 2-fold higher prevalence when compared with Caucasians (1.5%) and Hispanics
(1.3%; Kemmer & Neff, 2010). A leading cause of death for African Americans ages 4564 is HCV-related chronic liver disease (Pearlman, 2006). In addition, HCV-infected
African Americans are afflicted with poorer survival rates from liver transplant and
higher incidences of liver cancer and liver cancer-related mortality as compared to
Caucasians (Layden et al., 2012). When given treatment for HCV infection, African
Americans have lower rates of response and viral clearance compared to Caucasians
(Burton et al., 2012). A high prevalence of injection drug use combined with lower
socioeconomic status introduces limited access to health care, bias, stigmatization, and
inferior quality of care (Davila & El-Serag, 2006; Sloane et al., 2006). African
Americans experience disparities in access to care that are reflected in the outcome and
survival of HCV infection; along with the individual comorbidities that impact low
treatment rates, African Americans are disproportionately affected by lack of adequate
health insurance and high treatment costs (Melia et al., 2011). As of 2008, there have
been newer treatment options available that have substantially increased the rates of
sustained virologic response (SVR) for all genotype 1 infected persons, including African
Americans (Burton et al., 2012). The most recent data on HCV infection in the U.S.
population were collected by the 2011-2012 National Health and Nutrition Examination
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Survey (NHANES). In this quantitative study, I used secondary datasets from the
NHANES and the Hepatitis C Follow-Up Questionnaire (HCQ) for the years 2005-2012
to determine whether the seeking of health care by HCV-positive African Americans and
health care provider responses to HCV-positive African Americans had improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
In this chapter, I describe the research methodology, including the study design
and rationale. I also describe the study population, sampling strategy, and procedures for
sampling, recruitment, data collection, and quality assurance. The independent and
dependent variables and covariates are also defined and described. Lastly, I discuss
threats to validity, bias, methodological limitations, and ethical considerations.
Research Design and Rationale
This study used a quantitative, nonexperimental research design with crosssectional survey data from four 2-year NHANES datasets and HCQs (2005-2012) to
examine the health care seeking behavior and provider responses associated with HCVpositive African Americans, as compared to other HCV-positive racial/ethnic groups,
since 2008, when newer treatment options for HCV were made available in the United
States. The study compared the influence of race/ethnicity on health care seeking
behavior and provider responses of HCV-positive HCQ respondents within two time
periods, 2005-2008 and 2009-2012. The dependent variables were health care seeking
behavior and provider responses, and the independent variable was HCV-positive HCQ
respondents. The covariates included age, gender, race, education, poverty index, health
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insurance status, and history of illegal injection drug use. The research questions and null
and alternate hypotheses leading this study were as follows:
Research Question 1
Has the seeking of health care, as defined by self-report HCQ responses, by HCVpositive African Americans improved since 2008 following the introduction of new
treatment options as compared to other HCV-positive racial/ethnic groups?
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ
responses, by HCV-positive African Americans has not improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans has improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Research Question 2
Has the response from health care providers, as defined by self-report HCQ
responses, to HCV-positive African Americans improved since 2008 following the
introduction of new treatment options as compared to other HCV-positive racial/ethnic
groups?
Null hypothesis (H02): The response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans has not improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
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Alternative hypothesis (Ha2): The response from health care providers, as defined
by self-report HCQ responses, to HCV-positive African Americans has improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
Quantitative methodology was selected for this study because this method can be
used to analyze numerical data statistically to assess multiple variables, test hypotheses,
and explain a particular phenomenon (Muijs, 2010). The study hypotheses were tested
using numerical variables, which were quantified by statistical analysis. Correlational
research is conducted in order to determine the extent of a relationship between two or
more variables using statistical data and can be interpreted to recognize trends, but it does
not go so far in its analysis as to establish cause and effect (Muijs, 2010). Specific to this
study was the relationship that existed between the identified variables of health care
seeking behavior and provider responses with HCV-positive African Americans
compared to other racial/ethnic groups and two 4-year time periods, 2005-2008 and
2009-2012, which occurred before and after the introduction of newer treatment options,
respectively. By using quantitative statistical analysis, I was able to code data for
analysis of relationships between the key variables (Field, 2013). A qualitative research
design would not have been appropriate for this study because it would have involved
investigative methodologies such as ethnographic, naturalistic, anthropological, or
participant observer approaches (Key, 1997). Further, the qualitative method emphasizes
the importance of looking at variables in a natural setting in which they are found (Key,
1997).
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I conducted an inferential study to test the research hypotheses using secondary
data from a cross-sectional survey study. The use of cross-sectional survey data allows
the researcher to look at the relationship between variables, and if the survey is repeated,
the researcher can look at aggregate change over time in a population (King-Hele, 2005).
Benefits of using successive cross-sectional survey data over time include the following:
(a) a reasonable amount of comparability, (b) the data are representative at each specified
time point (e.g., years), and (c) it is possible to examine impact on groups (King-Hele,
2005). Limitations of using successive cross-sectional survey data over time include: (a)
reliance on the continuity of the data, (b) not being able to establish individual change,
and (c) inability to determine a causal relationship (King-Hele, 2005). Despite these
limitations, the use of secondary data from a cross-sectional survey study was appropriate
because this study investigated an association that had yet to be examined in the body of
scientific knowledge.
Other quantitative methods such as ex post facto, quasi-experimental, and true
experimental were not used because the purpose of those research methods did not fit the
research objective. Researchers conducting ex post facto studies investigate possible
cause-and-effect relationships by observing an existing condition or state of affairs and
searching back in time for plausible causal factors; those conducting true experimental
studies deliberately control and manipulate the independent variable to observe the effect
of that change on another dependent variable; and those conducting quasi-experimental
studies make comparisons between groups that are not equal, or comparisons within a
group over time (time-series; Creswell, 2009; Milstein & Wetterhall, 2013). In this study,
I evaluated whether health care seeking behavior and provider responses for HCV-
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positive African Americans, compared to other HCV-positive racial/ethnic groups, had
changed since the introduction of newer treatment options, and as such, quantitative
methodology using secondary data from a cross-sectional survey study was the
appropriate means by which to evaluate these outcomes among the study population
represented by NHANES 2005-2012. There were no time or resource constraints
anticipated for this study.
Methodology
Setting and Sample
This study used secondary data from four 2-year NHANES datasets (2005-2012).
All of these datasets provided the independent and dependent variables and covariates in
the public domain setting. The target population for NHANES is the noninstitutionalized
civilian population of the United States (Centers for Disease Control and Prevention,
2013a). The 2005-2012 NHANES datasets contained data for a total of 40,790 study
participants who were interviewed; of these, 39,303 (96.3%) participants underwent the
medical exam portion of the study (Centers for Disease Control and Prevention, 2014b).
Of the study participants who underwent the medical exam portion of the study, there
were 32,650 (83.0% of persons 6 years and older) who had serum samples drawn for the
screening hepatitis C antibody test (Centers for Disease Control and Prevention, 2014b).
The study population was defined as all NHANES participants 6 years of age and older
who tested positive for the anti-HCV antibody and were contacted during the follow-up
survey and interviewed. For the NHANES 2005-2012 datasets, the total number of study
participants who tested positive for the anti-HCV antibody was 394 (1.2% of all those
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screened), of those, 132 (33.0%) completed the Hepatitis C Follow-Up Questionnaire
(HCQ).
Sampling procedures. The NHANES used a stratified and multistage probability
sampling design and collected information from persons using standardized household
interviews, physical examinations, and testing of biologic samples; the data were
published in 2-year cycles (Ditah et al., 2014). The NHANES sampling procedure
consisted of four stages (Centers for Disease Control and Prevention, 2013a). Stage 1
was the primary sampling units (PSUs); these were selected from strata defined by
geography and proportions of minority populations, and were drawn mostly from single
counties in the United States (Centers for Disease Control and Prevention, 2013a).
Additional stages of sampling were performed to select for three secondary sampling
units: (a) segments (city blocks) that were selected by probability proportional to a
measure size, (b) households that were randomly drawn, and (c) individuals who were
randomly drawn with designated age-sex-race/ethnicity screening subdomains (Centers
for Disease Control and Prevention, 2013a). In order to obtain correct national estimates
from the NHANES data, each sampled person was assigned a numerical sample weight
(Centers for Disease Control and Prevention, 2013a). In addition, because the sample
was defined by strata and by the primary and secondary sampling units, the sampling
error was calculated on the counts of the groups, not the individuals; this also
demonstrated a more efficient data collection process (Centers for Disease Control and
Prevention, 2013a).
Power analysis. The sample size was chosen in relation to population size as a
result of a predefined subunit of the NHANES population: all HCV-positive participants
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who completed the HCQ in the time period of 2005-2012. The National Center for
Health Statistics analytic guidelines state that data from the Hepatitis C Follow-Up
Questionnaire (HCQ) should not be used with sample weights to make national estimates
because of the small sample size and a response rate below 50% (Denniston et al., 2012).
The statistical power of a study represents the probability that the researcher will
avoid making a Type I error of rejecting a null hypothesis that is true (Tomczak,
Tomczak, Kleka, & Lew, 2014). The higher or bigger the alpha level is (e.g., a = 0.05),
the more likely the researcher will be to reject a true null hypothesis (a Type I error); the
lower or smaller the alpha level is (e.g., a = .001), the more likely it is that the researcher
will accept a false null hypothesis (a Type II error; Tomczak et al., 2014).
I used G*Power v.3.1.9.2, an open domain statistical power analysis program, to
calculate the sample size based upon an analysis of variance (ANOVA) statistical test
(Buchner, Erdfelder, Faul, & Lang, 2013). The calculation with G*Power included the
following: (a) test family = F tests; (b) statistical test = ANOVA: fixed effects, special,
main effects, and interactions; (c) type of power analysis = a priori: compute required
sample size – given α, power, and effect size; (d) effect size f = .25 (as per Cohen’s
conventions for medium effect size); (e) alpha level = 0.05; (f) power = 0.80; (g)
numerator df = 1; and (h) number of groups = 2. The G*Power analysis calculated the
total sample size as 128 subjects.
Procedures for Recruitment, Participation, and Data Collection
The Division of Health and Examination Statistics releases NHANES public-use
data files on a biannual basis, which, according to the data user agreement, must be used
solely for the purpose of health statistical reporting and analysis as specified by the
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Public Health Service Act [Section 308 (d)] (Centers for Disease Control and Prevention,
2009b). The households that were randomly selected and identified for inclusion in the
NHANES sample were mailed an advance introductory letter informing them that an
NHANES interviewer would be visiting their home (Centers for Disease Control and
Prevention, 2010). Upon arriving at the home, the NHANES interviewer provided an
official identification badge; if the occupant had not seen the advance letter, a copy was
given to the occupant for review (Centers for Disease Control and Prevention, 2010).
The NHANES interviewer asked residents a few short questions (“Household Screener
Questionnaire Module”) to determine if their household was eligible for the study; if one
or more persons were selected to participate, consent forms were signed for both the
household interview and medical examination components of the survey (Centers for
Disease Control and Prevention, 2010).
Household interview component. The household interview component (HIC)
included demographic, socioeconomic, dietary, and health-related questions (Centers for
Disease Control and Prevention, 2013a). The NHANES computer-assisted personal
interview (CAPI) software program that was used to collect the interview data had builtin data edit and consistency checks (Centers for Disease Control and Prevention, 2013a).
The data edit checks alerted the interviewer when unusual or potentially erroneous data
values were recorded; the consistency checks were used to alert the interviewer when
information was recorded that was inconsistent with previous data entries or respondent
characteristics such as the respondent’s age (Centers for Disease Control and Prevention,
2013a). Additional assistance in the interview process included preprogrammed
questionnaire “skip” patterns to reduce respondent burden, as well as standardized

48
descriptions of the terminology and concepts that were used in the questionnaires
(Centers for Disease and Prevention, 2013a).
Medical examination component. If a participant had agreed to complete the
medical examination component (MEC), he or she was provided medical, dental, and
physiological measurements, as well as laboratory tests administered by a MEC survey
team (coordinator, manager, one physician, two dietary interviewers, three certified
medical technologists, four health technicians, one phlebotomist, two interviewers, and
one computer data manager; Centers for Disease Control and Prevention, 2010). Some of
the medical findings from the examination were given to the examinees before they
exited the MEC; the other reportable survey findings were mailed to participants after the
laboratory assays and special tests were completed (Centers for Disease Control and
Prevention, 2010).
Screening for Hepatitis C. Participants 6 years of age or older who tested
positive for anti-HCV antibody were sent a report of findings (ROF) letter that informed
them (or parents of participants < 18 years of age) of the following: (a) HCV test result,
(b) HCV transmission information, (c) effect on the liver, (d) effect on general health,
and (e) encouragement to follow up with a healthcare provider (Denniston et al., 2012).
Approximately 6 months following the ROF letter, a Hepatitis C Follow-Up
Questionnaire (HCQ) was administered over the telephone (Denniston et al., 2012).
Instrumentation and Materials
The NHANES is designed to assess the health and nutritional status of adults and
children in the United States; findings are used to determine the prevalence of major
diseases and risk factors for disease, as well as to expand health knowledge for the nation
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to inform health programs and services (Centers for Disease Control and Prevention,
2013a). Based upon this scope, the NHANES survey represented the most applicable
source of data for this study.
Age, gender, race, education, poverty index, health insurance status, and history
of illegal injection drug use were collected via household interview component. AntiHCV antibody level was determined via blood sample collected via venipuncture during
the medical examination component of the survey. Health care seeking behavior and
provider response questions were collected using the 2005-2012 HCQs. The 2005-2012
Demographics modules collected the age, gender, race, education, and poverty index
variables. The 2005-2012 Questionnaire modules collected the variables of health
insurance status, and history of illegal injection drug use.
Study variables and covariates. A list of the independent variable, dependent
study variables derived from the HCQ, and the covariates are provided in Table 1.
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Table 1
Independent and Dependent Variables and Covariates Used in This Study
Variable type

Variable name

Value

Anti-HCV antibody

Variable source and
label
MEC, LBDHCV

1,2,5

Level of
measurement
Categorical

Independent

Hepatitis C RNA

MEC, LBXHCR

1,2

Categorical

Seen a doctor about test
result?

HCQ, HCQ070

1,2

Categorical

Dependent

Have a doctor’s
appointment?

HCQ, HCQ080

1,2

Categorical

Dependent

Why not treated? (patient
decision)

HCQ, HCQ140A-E

1,2

Categorical

Did doctor do additional
tests?

HCQ, HCQ090

1,2

Categorical

Dependent

What doctor told about
test result?

HCQ, HCQ100

1,2,3,4

Categorical

Dependent

Ever had a liver biopsy?

HCQ, HCQ110

1,2

Categorical

Dependent

Doctor advised about
medications?

HCQ, HCQ121

1,2

Categorical

Dependent

Doctor advised you should
be treated?

HCQ, HCQ124

1,2

Categorical

Dependent

Doctor advised you should
not be treated?

HCQ, HCQ126A-E

1,2

Categorical

Dependent

Treated with these
medicines?

HCQ, HCQ130

1,2

Categorical

Covariate

Gender

Demographics module,
RIAGENDR

1,2

Categorical

HCQ—Health
Care Seeking
Dependent

HCQ - Provider
Response
Dependent

(table continues)
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Variable type

Variable name

Variable source and
label
Demographics module,
RIDAGEYR

Value
0 to 85

Level of
measurement
Continuous

Covariate

Age

Covariate

Race/Ethnicity

Demographics module,
RIDRETH1

1,2,3,4,5

Categorical

Covariate

Education (respondent 619 years old)

Demographics module,
DMDEDUC3

0 to 15

Categorical

Covariate

Education (respondent
20+ years old)

Demographics module,
DMDEDUC2

1,2,3,4,5

Categorical

Covariate

Poverty Index

Demographics module,
INDFMPIR

0 to 5.0

Continuous

Covariate

Health insurance status

Health insurance
module, HIQ011

1,2

Categorical

Covariate

History of
illegal injection drug use

Drug use module,
DUQ370

1,2

Categorical
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Table 2
Variable Source and Labels—Descriptions
Variable label
MEC
LBDHCV
LBXHCR
HCQ
RIAGENDR
RIDAGEYR
RIDRETH1
DMDEDUC3
DMDEDUC2
INDFMPIR
HIQ
DUQ

Description
Medical examination component
Hepatitis C antibody (confirmed)
Hepatitis C RNA (HCV-RNA)
Hepatitis C Follow-Up Questionnaire
Gender
Age at screening
Race/Ethnicity
Education Level—Children/Youth 6-19
Education Level—Adults 20+
Poverty income ratio (PIR)
Health insurance
Drug use

Independent variable. The independent variable, anti-HCV antibody, is a value
that was calculated on all examinees 6 years or older by a serum specimen with
laboratory testing as follows: samples testing positive for anti-HCV by the screening test
were tested in the confirmatory RIBA assay for antibody to hepatitis C virus; samples
with a positive RIBA result were reported as confirmed positive for antibody to HCV
(Centers for Disease Control and Prevention, 2012c). Samples with a negative RIBA
result were reported as such (Centers for Disease Control and Prevention, 2012c).
Samples with an indeterminate RIBA result were tested for hepatitis C RNA (HCVRNA). For inferential statistics, anti-HCV antibody was a categorical variable and
reported as positive (1), negative (2), or indeterminate (3); HCV-RNA was a categorical
variable and reported as positive (1), or negative (2). Subjects who had positive antiHCV or positive HCV-RNA were included in the analysis. Subjects who had negative or
missing values were excluded from analysis.
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Dependent variables. The dependent variables were a specific series of questions
from the HCQ that examined health care seeking behavior and provider responses. Each
variable had self-reported responses, and each variable was individually evaluated during
the study analyses.
Health care seeking behavior variables. Health care seeking behavior variables
from the HCQ for this study included the following:
•

Seen a doctor about test result? The test result was defined as either the
participant’s first positive hepatitis C test, or the NHANES positive hepatitis
C test. This was a categorical variable and was reported as (1) yes, and (2) no.

•

Have an appointment to see a doctor about test result? This was a categorical
variable and was reported as (1) yes, and (2) no.

•

Why did you decide not to be treated? This was a categorical variable that
was reported as (1) yes, and (2) no for each of the 5 options provided by the
interviewer: (a) side effects are unpleasant, (b) need to self-inject the medicine,
(c) too expensive, (d) hope of better future treatments, and (e) some other
reason given.

Provider response variables. Provider response variables from the HCQ for this
study included the following:
•

Did doctor do additional tests? This was a categorical variable and was
reported as (1) yes, and (2) no.

•

What doctor told you about test result? This was a categorical variable and
was reported as (1) hepatitis C and needs a regular medical follow-up, (2)
tested positive for hepatitis C, but do not need to do anything or worry about it,

54
(3) really don’t have hepatitis C because a follow-up test showed that the
positive test result was in error, and (4) Other.
•

Ever had a liver biopsy? This was a categorical variable and was reported as
(1) yes, and (2) no.

•

Doctor advised about medications used to treat hepatitis C? This was a
categorical variable and was reported as (1) yes, and (2) no.

•

Doctor advised you should be treated with medication such as interferon and
ribavirin? This was a categorical variable and was reported as (1) yes, and (2)
no.

•

Doctor advised you should not be treated? This was a categorical variable
that was reported as (1) yes, and (2) no for each of the 5 options provided by
the interviewer: (a) liver enzymes were normal, (b) did not have liver disease,
(c) do not need to do anything, (d) can wait to be treated at a later time, and
(e) no reason given.

•

Treated with these medicines? This was a categorical variable and was
reported as (1) yes, and (2) no.

Covariates. Confounding variables for this study included gender, age, race,
education, poverty index, health insurance status, and history of illegal injection drug use.
•

Gender. Gender was a categorical variable and was reported as either male
(1) or female (2). All subjects had a reported gender. There were no missing,
refused, or unknown values for the sample population.
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•

Age. Age was calculated based on participants’ date of birth. If the actual
date of birth was missing, then the reported age was used. For NHANES
2005-2006, age in years was reported as a continuous variable with ages
between 1 and 84 years of age, and all adults who were 85 years and older
were categorically assigned a value of ‘85’. For NHANES 2007-2012, age in
years was reported as a continuous variables with ages between 1 and 80 years
of age, and all adults who were 80 years and older were categorically assigned
a value of ‘80’. All subjects had a reported age. There were no missing,
refused, or unknown values for the sample population. For the inferential
analysis, the age variable was recoded into age groups reported as (1) <30
years, (2) 30-49 years (3) 50-69 years, and (4) 70+ years. These age groups
were chosen to capture the young persons (<30 years) and baby boomer (5069 years) cohorts at risk for HCV infection. Seventy-five percent of all
persons living with HCV infection and 75% of HCV-associated deaths are
attributed to those who were born during the years of 1945 to 1965 (a.k.a.,
baby boomers; Centers for Disease Control and Prevention, 2015a). In 2011,
the Centers for Disease Control and Prevention Hepatitis C Surveillance found
the largest increases in rate of acute hepatitis C among persons aged 0-29
years when compared to all age groups; in addition, researchers found a trend
of increasing HCV infections among adolescents and young adults in the
United States (Centers for Disease Control and Prevention, 2014c).

•

Race/Ethnicity. This was a categorical variable and was reported as Mexican
American (1), Other Hispanic (2), Non-Hispanic White (3), Non-Hispanic
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Black (4), and Other Race – Including Multi-Racial (5). If respondents selfidentified as “Mexican American” they were coded as such; if respondents
self-identified as “Hispanic” they were coded as “Other Hispanic” (Centers
for Disease Control and Prevention, 2012c). All other respondents were
categorized based on their self-reported races as coded above. There were no
missing, refused, or unknown values for the sample population. For the
inferential analysis, the race variable was recoded into three categorical
groups reported as (1) Caucasian, (2) African American, and (3)
Hispanic/other.
•

Education. There were two scales used for this categorical variable: ages 6-19
years and 20+ years. For those ages 6-19 years, the codes were the highest
grade or level of education and reported as (0) never attended/kindergarten
only, (1-12) single grades 1 thru 12, (13) high school graduate, (14) GED or
equivalent, and (15) more than high school. For those ages 20 and over, the
codes were reported as (1) less than 9th grade, (2) 9-11th grade (includes 12th
grade with no diploma), (3) high school graduate/GED or equivalent, (4) some
college or AA degree, and (5) college graduate or above. There were no
missing, refused, or unknown values for the sample population. For the
inferential analysis, the education variable for ages 6-19 years was recoded
into the same education groups as the ages 20 years and older scale. This
allowed the merging of all persons ages 6 and older into the following
education groups reported as (1) less than high school (includes 12th grade
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with no diploma), (2) high school graduate/GED or equivalent, (3) more than
high school, and (4) Don’t know.
•

Poverty Index. This number was calculated by dividing family income by the
poverty guidelines, specific to family size, as well as the appropriate year and
state. This continuous variable was reported as a range value from 0 to 5.00
with values at or above 5.00 coded as 5.00 or more. For the inferential
analysis, the poverty index variable was recoded into three categorical groups
reported as (1) < 1.0 (below poverty level), (2) 1.0-1.9 (near poverty level),
and (3) 2.0 or greater (above poverty level). There were 15 missing values for
the sample population.

•

Health Insurance Status. This was a categorical variable and was reported as
(1) yes or (2) no. There were no missing, refused, or unknown values for the
sample population.

•

History of Illegal Injection Drug Use. This was a categorical variable and was
reported as (1) yes or (2) no. The age groups for each of the NHANES
datasets that was released for this variable included: 2005-2006 ages 20-59,
2007-2008 ages 20-69, 2009-2010 ages 18 and older, 2011-2012 ages 18-69.
There were 19 missing values for the sample population.

Data Analysis Plan
NHANES 2005-2012 data were released to the public in SAS transport files
(Centers for Disease Control and Prevention, 2013c). All relevant data files required for
the study were opened by the software application Statistical Package for the Social
Sciences (SPSS) version 21.0, and then converted and used in SAV format for all data
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analyses that was performed. SPSS was suitable for this study because it was able to do
merging, coding, and recoding of data, in addition to generating tabulated reports, charts,
plots of distributions and trends, descriptive statistics, and complex data manipulation
and analysis (Field, 2013).
The 2005-2012 NHANES data sets that were downloaded from the Centers for
Disease Control and Prevention website included: (a) demographics, (b) health insurance,
(c) drug use, (d) laboratory – hepatitis C, and (e) HCQ. Frequency counts were
performed and matched against reported frequencies for each variable in the Data
Documentation, Code Book and Frequencies reports for the years 2005-2012 issued by
the Centers for Disease Control and Prevention (2013a). All survey data had built in edit
and consistency checks and quality control measures after collection including staff
review and external verification with respondents (Centers for Disease Control and
Prevention, 2013b). The NHANES Medical Examination Component laboratory is a
Clinical Laboratory Improvement Act (CLIA)-certified lab and used both internal and
external surveillance measures to monitor quality assurance and quality control (Centers
for Disease Control and Prevention, 2014d). Missing values counts from downloaded
data variables were verified against the CDC reported missing value counts in the public
files. All missing values were deleted and excluded for analysis thus eliminating any
potential for missing value bias. I used both descriptive and inferential statistics in this
study. Descriptive statistics simply describes what is or what the data shows with simple
summaries about the sample and the measures; inferential statistics allows the researcher
to try and reach conclusions that extend beyond the immediate data alone (Field, 2013).
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Descriptive statistics. The characteristics of participants for the NHANES data
set were summarized into two time periods, 2005-2008 and 2009-2012, using a frequency
table that reports the number and percentage of occurrence. This included: (a) total
number of participants who completed the HIC and MEC, (b) total number of participants
who had a serum sample tested for anti-HCV antibody, (c) total number of participants
who were anti-HCV positive, and (d) total number of participants who completed the
HCQ. The characteristics of the participants who completed the HCQ were reported in
two time periods, 2005-2008 and 2009-2012, using a frequency table and included the
number and percentage for the covariates of age, gender, race, education, poverty index,
health insurance status, and history of illegal injection drug use. The characteristics of
the participants who completed the HCQ were reported by three racial/ethnic groups
(Caucasian, African American, Hispanic/Other) in two time periods, 2005-2008 and
2009-2012, and used a frequency table that included the number and percentage for the
covariates of age, gender, education, poverty index, health insurance status, and history
of illegal injection drug use.
Inferential statistics. Inferential statistical methods were used to answer the
research questions. The chi-square test for independence was used to examine if there
was a relationship between two or more categorical variables (Laerd Statistics, 2013). In
order to conduct this test, two assumptions needed to be met: (a) the two variables should
be measured at an ordinal or nominal level, and (b) the two variables should consist of
two or more categorical, independent groups (Laerd Statistics, 2013). This method was
appropriate to test the hypotheses of the study as it did not require normal distribution or
variance assumptions about the populations from which the samples were drawn and was
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designed for ordinal or nominal data (Laerd Statistics, 2013). For each of the 10
dependent variables (HCQ responses), a chi-square test for independence was conducted
with three racial/ethnic groups (Caucasian, African American, Hispanic/Other) to
compare the differences with their health care seeking behavior and provider responses
before the introduction of new treatment options (time period 2005-2008) and after the
introduction of new treatment options (time period 2009-2012). If the sample size was
smaller than 5, a Fisher’s exact test was conducted. In order to account for confounders,
I used multiple logistic regression and explored the associations between the HCQ
responses of each racial/ethnic group in two time periods as described above. The
multiple logistic regression model included the covariates of age, gender, education,
poverty index, health insurance status, and history of illegal injection drug use. Specific
statistical methods used to test the hypotheses are described below.
Research Question 1. Has the seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans improved since 2008 following the
introduction of new treatment options as compared to other HCV-positive racial/ethnic
groups?
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ
responses, by HCV-positive African Americans has not improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans has improved since 2008 following
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the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
To test Research Question 1, a chi-square test for independence was conducted
with three categorical independent HCV-positive racial/ethnic groups who were HCQ
respondents (Caucasian, African American, Hispanic/Other). Each racial/ethnic group’s
HCQ answers were compared for two time periods (2005-2008 and 2009-2012). Health
care seeking behavior was defined as the following three HCQ answers: (a) I saw a
doctor about the hepatitis C test result, (b) I have an appointment to see a doctor about the
hepatitis C test result, and (c) I decided not to get treated because (5 choices): side effects
are unpleasant, need to self-inject medicine, too expensive, hope of future better
treatments and, some other reason given. An improvement is defined as an increase in
the number of individuals who saw a doctor or have an appointment to see a doctor, and a
decrease in the number of individuals who decided not to get treated. Any probability
value of significance (p-value) which is less than or equal to the level of significance
(0.05) was considered statistically significant. Given that multiple factors can influence
health care seeking behavior, a multivariable logistic regression analysis was conducted
in order to determine the independent relation between the three HCQ answers of HCVpositive participants in two time periods (2005-2008 and 2009-2012) after controlling for
the covariates of age, gender, race/ethnicity, education, poverty index, health insurance
status, and history of illegal injection drug use.
Research Question 2. Has the response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans improved since 2008
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following the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups?
Null hypothesis (H02): The response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans has not improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
Alternative hypothesis (Ha2): The response from health care providers, as defined
by self-report HCQ responses, to HCV-positive African Americans has improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
To test Research Question 2, a chi-square test for independence was conducted
with three categorical independent HCV-positive racial/ethnic groups who were HCQ
respondents (Caucasian, African American, Hispanic/Other). Each racial/ethnic group’s
HCQ answers were compared for two time periods (2005-2008 and 2009-2012). The
response from health care providers was defined as the following seven HCQ answers:
(a) the doctor did other blood tests to check the liver, (b) the doctor told me I need regular
medical follow-up, (c) the doctor told me I do not need to do anything or worry about my
hepatitis C, (d) I had a liver biopsy, (e) the doctor told me there are medicines that can be
used to treat hepatitis C, (f) I was treated with the medication, (g) the doctor told me I
should not be treated because (5 choices): liver enzymes are normal, do not have liver
disease, don’t need to do anything, wait to be treated at a later time and, no reason
specified. For response from health care providers, an improvement was defined as an
increase in the number of individuals who: (a) had additional tests done, (b) need regular
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medical follow-up, (c) had a liver biopsy, (d) informed there are medicines that can be
used to treat hepatitis C, and (e) who were given medication for their HCV infection.
Any probability value of significance (p-value) which is less than or equal to the level of
significance (0.05) was considered statistically significant. Given that multiple factors
can influence responses from a health care provider, a multivariable logistic regression
analysis was conducted in order to determine the independent relation between the seven
HCQ answers of HCV-positive participants in two time periods (2005-2008 and 20092012) after controlling for the covariates of age, gender, race/ethnicity, education,
poverty index, health insurance status, and history of illegal injection drug use.
Threats to Internal and External Validity
There are threats that exist with both internal and external validity and can occur
at any time during the research process (Creswell, 2009). The NHANES has been utilized
as a nationwide surveillance system for over 40 years; in addition, the analyses of
responses from the U.S. noninstitutionalized adult population indicated that the
NHANES measures had good construct validity (Centers for Disease Control and
Prevention, 2013a). In using secondary data analysis, assessing the validity of the
measures includes examining the questions that were asked for face validity; there is a
threat if the questions are found to be meaningless, problematic or open to a range of
interpretation (Creswell, 2009). Internal validity is focused on the study design and the
degree of control applied over potential extraneous variables that can threaten the internal
validity (Slack & Draugalis, 2001). This control can lessen the potential for alternative
explanations for treatment effects while consequently providing more confidence that the
effects are due to the independent variable (Slack & Draugalis, 2001). When a researcher
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draws incorrect inferences from the study data to other past or future settings it introduces
threats to external validity (Creswell, 2009).
With regard to the validity of the NHANES survey instrument, a thorough
examination of the instrument will include information on all three types of validity:
content, construct, and empirical (Frankfort-Nachmias & Nachmias, 2008). To ensure
content validity of this instrument, face validity can be utilized to compare the questions
to other questionnaires on the same subject (e.g. hepatitis c status, health status;
Frankfort-Nachmias & Nachmias, 2008). For the launch of the continuous survey, and
biannually after the survey began, new content proposals were solicited and ascertained if
they were safe, feasible, and of sufficient public health significance, as well as
appropriateness and feasibility, to include in NHANES (Centers for Disease Control and
Prevention, 2013d). This demonstrated an establishment of construct validity by
determining whether the instrument is logically and empirically tied to the concepts and
theoretical assumptions that are being employed in the research studies (FrankfortNachmias & Nachmias, 2008). If the proposal was accepted, the protocol was fully
developed and prepared for field-testing prior to use in NHANES (Centers for Disease
Control and Prevention, 2013d). This addressed the empirical validity of the instrument
by examining the relationship between the measuring instrument and the measured
outcomes, as they relate to the real world and the variables being measured (FrankfortNachmias & Nachmias, 2008). With regard to laboratory methods, they were tested and
deemed reliable and valid prior to their inclusion in NHANES (Centers for Disease
Control and Prevention, 2013d).
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Bias and Methodological Limitations
Bias is the result of systematic errors in the research study that result in an
incorrect estimate of the association between exposures and outcomes. The types of
biases addressed here include sampling bias, selection bias, nonresponse bias, and recall
bias. Methodological limitations are also addressed which may impact or limit further
studies.
Bias in sampling is a systematic error in sampling procedures that leads to a
distortion in the results of the study and eliminates the representativeness of the sample
(Frankfort-Nachmias & Nachmias, 2008). The NHANES sampling procedure consisted
of four stages (Centers for Disease Control and Prevention, 2013a). Stage 1 was the
primary sampling units (PSUs); these were selected from strata defined by geography and
proportions of minority populations, and were mostly single counties in the United States
(Centers for Disease Control and Prevention, 2013a). Additional stages of sampling were
performed to select for three secondary sampling units: (a) segments (city blocks) that
were selected by probability proportional to a measure size, (b) households that were
randomly drawn, and (c) individuals that were randomly drawn with designated age-sexrace/ethnicity screening sub-domains (Centers for Disease Control and Prevention,
2013a). In order to obtain correct national estimates from the NHANES data, each
sampled person was assigned a numerical sample weight (Centers for Disease Control
and Prevention, 2013a). In addition, because the sample is defined by strata and by the
primary and secondary sampling units, the sampling error was calculated on the counts of
the groups, not the individuals; this also demonstrated a more efficient data collection
process (Centers for Disease Control and Prevention, 2013a). Overall, the NHANES
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dataset assisted with controlling for sampling bias because it did not favor one group over
another, but used a cross-section of all persons who reply to be surveyed in the United
States (Frankfort-Nachmias & Nachmias, 2008). In this same vein, selection bias was
also reduced using this complex sampling method of patient selection.
Nonresponse bias occurs when some respondents included in the sample do not
respond (Creswell, 2009). Because NHANES used a complex sample design, sample
weights were used to account for stratification, clustering, and the unequal probability of
subject selection into the survey (Perlin, 2003). Each NHANES oversampled certain
population subgroups, and this was taken into account through appropriate weighting.
The issue of using weights was critical to the correct analysis of NHANES data;
inappropriate use of weights may have resulted in a flawed analysis and questionable
study results (Perlin, 2003). Sample weights were also used to adjust for possible bias
resulting from subject nonresponse (Perlin, 2003). Nonresponse is a key issue with any
survey, and nonresponse bias needs to be assessed, reported, and include any information
on reasons for missing data (Perlin, 2003).
In addressing methodological limitations, when analyzing the NHANES data,
sample weights were used to produce correct population estimates because each sample
weight does not have equal probability of selection into the survey (Perlin, 2003).
Although the current NHANES was conducted using annual samples that are nationally
representative, the sample size in any one year was relatively small, resulting in large
variability for estimates, especially with detailed analyses such as the study’s primary
cohort of only HCV-positive participants (Perlin, 2003). Another analytic limitation is
that the NHANES sample was selected from a relatively small number of sampling units
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(PSUs) or counties which can introduce a higher level of uncertainty in the annual
estimates (Perlin, 2003). The computation of 2-year datasets was preferred to decrease
variability in annual estimates.
Ethical Procedures and Considerations
Institutional Review Board (IRB) approval is required for all research involving
human subjects. Human subjects are defined as one or more living individuals about
whom an investigator (whether professional or student) conducting research obtains (a)
data through intervention or interaction with the individual or, (b) identifiable private
information (U.S. Department of Health and Human Services, 2014). This study used
archived, deidentified secondary data that had been released by the Centers for Disease
Control and Prevention (2012b) to the public domain and may be reproduced without
permission; therefore, I did not need to obtain informed consent. This study received
Walden University Institutional Review Board approval prior to any data analysis (IRB
Approval Number: 08-06-15-0171822). In doing so, I was protecting the University, the
study participants, and myself by ensuring that my dissertation research was in
compliance with the University’s ethical standards as well as U.S. federal regulations
(Walden University, 2014). Regarding the IRB’s process for NHANES, the National
Center for Health Statistics had a Research Ethics Review Board that approved each
NHANES survey; the protocol number and approval information can be obtained and
referenced from the Centers for Disease Control and Prevention (2012b) website:
http://www.cdc.gov/nchs/nhanes/irba98.htm
The main ethical consideration with this research study was the protection of the
survey participants’ identity. In order to protect subject confidentiality, the NHANES did
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not include certain information (e.g., subject address or location, date of birth) with the
publically available data; in addition, many data elements were never be made available
to the public (Perlin, 2003). Laboratory samples, medical examinations, and survey
responses were all deidentified and identifier code numbers were used in place of names
or other identifying information (Centers for Disease Control and Prevention, 2012b).
With HCV testing, the only demographic information attached to the HCV serum
samples was age in 20-year groups, sex, race or ethnic group, and sampling location
(Perlin, 2003).
Prior to the Centers for Disease Control and Prevention (2012b) collecting the
health information for the NHANES, they obtained informed consent from all survey
participants assuring them that data collected was only to be used for stated purposes and
would not be disclosed or released to others without consent of the individual or the
establishment “in accordance with section 308(d) of the Public Health Service Act”. An
informed consent was provided to disclose that blood samples were to be tested, and
maximum safeguards would be utilized to protect each sample person’s confidentiality
(Perlin, 2003). The NHANES consent also informed participants that the Centers for
Disease Control and Prevention (2011) allowed other collaborators and researchers to use
survey data, but their privacy was protected by the assignment of code numbers in place
of names, and abstaining from revealing any other facts that could directly identify the
person. Storage of all data will be maintained in two locations, a laptop computer and an
external hard drive, for no less than five years upon completion of the dissertation, and
with sole accessibility of myself only. This study was performed to fulfill the
requirements for the Doctorate of Philosophy in Public Health and Epidemiology at
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Walden University. I have no financial interest in Walden University and claim no
financial or other conflicts of interest with any other party.
Summary
In Chapter 3, I presented the detailed methodology of this research study, which
included the research design and approach used to address the research questions and
hypotheses. Additionally, I discussed the setting and sample of the study and described
procedures for sampling, subject recruitment, and data collection. I also discussed the
instrumentation validity and reliability and operationalization of the variables. Threats to
validity and ethical considerations were also discussed in this chapter. In Chapter 4, I
discuss the results of the statistical analyses, as well as the results of each of the research
questions.
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Chapter 4: Results
Introduction
The purpose of this study was to examine health care seeking behavior and
provider responses for HCV-positive African Americans in the noninstitutionalized U.S.
population. The research questions and associated null hypotheses for this study were:
Research Question 1: Has the seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans improved since 2008 following the
introduction of new treatment options as compared to other HCV-positive racial/ethnic
groups?
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ
responses, by HCV-positive African Americans has not improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report
HCQ responses, by HCV-positive African Americans has improved since 2008 following
the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups.
Research Question 2: Has the response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans improved since 2008
following the introduction of new treatment options as compared to other HCV-positive
racial/ethnic groups?
Null hypothesis (H02): The response from health care providers, as defined by
self-report HCQ responses, to HCV-positive African Americans has not improved since
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2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
Alternative hypothesis (Ha2): The response from health care providers, as defined
by self-report HCQ responses, to HCV-positive African Americans has improved since
2008 following the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups.
These hypotheses were tested using secondary data from the National Health and
Examination Survey (NHANES) 2005-2012, which was a stratified, multistage
probability sample of the civilian, noninstitutionalized U.S. population. The study
analyzed data from participants who tested positive for past or current HCV infection and
were interviewed as part of the Hepatitis C Follow-Up Questionnaire (HCQ) during the
NHANES conducted from 2005 through 2012. The associations between dichotomous
HCQ responses from three racial/ethnic groups (Caucasian, African American,
Hispanic/Other) were compared to evaluate the differences in health care seeking
behavior and provider responses before the introduction of new treatment options (time
period 2005-2008) and after the introduction of new treatment options (time period 20092012) using chi-square test of independence. If the sample size was smaller than 5, a
Fisher’s exact test was conducted. The associations between the HCQ responses of each
of the three racial/ethnic groups from two time periods, 2005-2008 and 2009-2012, with
the covariates of age, gender, education, poverty index, health insurance status, and
history of illegal injection drug use, were analyzed using binomial logistic regression.
In this chapter, I present the descriptive statistics of the dichotomized dependent
and independent variables as well as the study covariates. I also present the results for
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the inferential statistics analysis and hypothesis testing for the two research questions, as
well as summarize the significant findings as they relate to the research questions.
Data Collection
The secondary source of the data, the NHANES survey, used a stratified and
multistage probability sampling design and collected information from persons using
standardized household interviews, physical examinations, and testing of biologic
samples; the data were published in 2-year cycles (Centers for Disease Control and
Prevention, 2013a). The NHANES sampling procedure consisted of four stages (Centers
for Disease Control and Prevention, 2013a). Stage 1 was the primary sampling units
(PSUs); these were selected from strata defined by geography and proportions of
minority populations and were mostly single counties in the United States (Centers for
Disease Control and Prevention, 2013a). Additional stages of sampling were performed
to select for three secondary sampling units: (a) segments (city blocks) that were selected
by probability proportional to a measure size, (b) households that were randomly drawn,
and (c) individuals who were randomly drawn with designated age-sex-race/ethnicity
screening subdomains (Centers for Disease Control and Prevention, 2013a). In order to
obtain correct national estimates from the NHANES data, each sampled person was
assigned a numerical sample weight (Centers for Disease Control and Prevention, 2013a).
In addition, because the sample was defined by strata and by the primary and secondary
sampling units, the sampling error was calculated on the counts of the groups, not the
individuals; this also demonstrated a more efficient data collection process (Centers for
Disease Control and Prevention, 2013a). Data for the 2005 through 2012 surveys were
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collected between January 2005 and December 2012 (Centers for Disease Control and
Prevention, 2013a).
For the NHANES 2005 through 2012, a total of 40,790 participants completed the
household interview component (HIC); of these, a total of 39,303 (96.3%) participants
underwent the medical examination component (MEC; Centers for Disease Control and
Prevention, 2014b). Participants 6 years of age or older who had a positive test result for
anti-HCV or, beginning in 2007, had an indeterminate test result for anti-HCV and a
positive HCV-RNA, were sent a report of findings (ROF) letter informing them, or the
parents of individuals < 18 years of age, of their HCV test result and encouraging them to
follow up with a health care provider. Approximately 4 to 5 months after the ROF was
mailed, a Hepatitis C Follow-Up Questionnaire (HCQ) was administered by telephone.
Persons > 18 years of age were interviewed directly; an adult proxy provided information
for individuals < 18 years of age and for individuals unable to answer themselves. The
HCQ was mentioned in the informed consent and also in the ROF letter. The sample for
analysis was all individuals who completed the HCQ 2005 through 2012.
Results
Univariate Analysis
NCHS analytic guidelines state that data from the Hepatitis C Follow-Up
Questionnaire (HCQ) should not be used with sample weights to make national estimates
because of small sample size and a response rate below 50% (Centers for Disease Control
and Prevention, 2012c). Therefore, analyses were conducted in SPSS 21.0 using chisquare and, where appropriate (i.e., small cell sizes), Fisher’s exact tests. Percentages
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reported are percentages of respondents, not population estimates. Results were
considered statistically significant at the 0.05 level.
Data from four 2-year cycles (2005-2012) of the Hepatitis C Follow-Up
Questionnaire were combined with the NHANES demographic information, health
insurance, and injection drug use data. As shown in Table 3, a total of 32,630 (83.0%)
participants had serum samples drawn for the screening hepatitis C antibody test; the total
number of individuals who had a positive HCV result was 394 (1.2% of all those
screened), of which 132 (33.5%) completed the Hepatitis C Follow-Up Questionnaire
(HCQ).
Table 3
Characteristics of Participants, NHANES, Time Periods 2005-2008 and 2009-2012

Completed HIC and MEC*

NHANES
2005-2012
40,790
N
%
39,303 96.3

NHANES
2005-2008
20,497
N
%
19,712 96.2

NHANES
2009-2012
20,293
N
%
19,591 96.5

Tested for anti-HCV

32,630

83.0

16,218

82.3

16,412

83.8

394

1.2

194

1.2

200

1.2

Number of participants

Positive for anti-HCV**

Completed HCQ***
132 33.5
66 34.0
66 33.0
* = Household interview component and medical examination component.
** = All positive anti-HCV results and indeterminate anti-HCV results that tested
positive for HCV-RNA.
*** = Hepatitis C Follow-Up Questionnaire.
All results pertain to the “study sample” of 132 individuals who tested positive for
current or past infection and responded to the HCQ, and are compared in two 4-year time
periods, 2005-2008 and 2009-2012; therefore, these results are not generalizable. Table 4
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reports the frequencies and percentages for the categorical variables of characteristics for
the study sample (n = 132), the 2005-2008 sample (n = 66), and the 2009-2012 sample (n
= 66). Using chi-square test of difference between the two time periods, participants in
the 2005-2008 time period were more likely to be younger than age 50 (p < 0.05) and
Caucasian (p < 0.05) as compared to participants in the 2009-2012 time period (Table 4).
The results demonstrated no statistically significant difference of participants between the
two time periods when comparing the characteristics of gender, education, poverty index
level, health insurance status, and history of illegal injection drug use.
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Table 4
Characteristics of Participants, NHANES Hepatitis C Follow-Up Questionnaire,
Time Periods 2005-2008 and 2009-2012
Study
sample
132
N
%

Sample size

2005–2008
sample
66
N
%

2009–2012
sample
66
N
%

P value*

Age group (years)
< 30
30-49
50-69
70 +

3
46
77
6

2.3
34.8
58.3
4.6

3
30
33
0

4.5
45.5
50.0

0
16
44
6

24.2
66.7
9.1

Male
Female

83
49

62.9
37.1

39
27

59.1
40.9

44
22

66.7
33.3

<0.05

Gender
Race/ethnicity
Caucasian
51 38.6
33 50.0
18 27.3
< 0.05
African American
47 35.6
20 30.3
27 40.9
Hispanic/other
34 25.8
13 19.7
21 31.8
Education
Less than high schoola
45 34.1
18 27.2
27 40.9
HS graduate/GED
40 30.3
28 42.5
12 18.2
More than high school
46 35.1
20 31.3
26 39.3
Don’t know
1
1.0
1
1.5
Income
Below poverty level
33 28.2
14 23.3
19 33.3
Near poverty level
44 37.6
26 43.3
18 31.6
Above poverty level
40 34.2
20 33.3
20 35.1
Missing
6
9
Health insurance
Yes
95 71.2
50 75.8
45 68.2
No
37 28.0
16 24.2
21 31.8
History of illegal
injection drug use
Yes
57 50.4
29 49.2
28 51.9
No
56 49.6
30 50.8
26 48.1
Missing
7
12
* = P value for chi-square test of difference between time periods 2005-2008 and 20092012. (Fisher’s exact test used for small cell sizes).
a = includes 12th grade with no diploma.
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The characteristics of the study sample were also analyzed by three racial/ethnic
groups (Caucasian, African American, and Hispanic/Other) between the two time periods,
2005-2008 and 2009-2012, and reported as frequencies and percentages as shown in
Table 5. Using chi-square test of difference to compare each racial/ethnic group (e.g.
Caucasian v. Caucasian) between the two time periods, the Hispanic/Other group in the
2005-2008 time period were more likely to be younger than 50 years of age (p < 0.05) as
compared to the Hispanic/Other group in the 2009-2012 time period. The results
demonstrated no additional statistically significant difference with each racial/ethnic
group between the two time periods when comparing the characteristics of gender,
education, poverty index level, health insurance status, and history of illegal injection
drug use.
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Table 5
Characteristics of Participants by Race/Ethnicity, NHANES Hepatitis C Follow-Up
Questionnaire, Time Periods 2005-2008 and 2009-2012
2005–2008
sample
(N = 66)
Caucasian African Hispanic/
American
Other

Race/Ethnicity

N

%

N

2009–2012
sample
(N = 66)
Caucasian African Hispanic/
American
Other

%

N

%
33.3*
20.0*
18.2
0.0

0
6
12
0

0.0
37.5
27.3
0.0

0
0.0 0
3 18.8 7
18 40.9 14
6 100.0 0

0.0
43.8
31.8
0.0

Age group (years)

N

%

N

%

N

%

< 30
30-49
50-69
70 +

2
19
12
0

66.7
63.3
36.4
0.0

0
5
15
0

16.7
45.5
0.0

1
6
6
0

Male
Female

20
13

51.3
48.1

12
8

30.8
29.6

7
6

17.9
22.2

12
6

27.3
27.3

18
9

40.9 14
40.9 7

31.8
31.8

Less than
high school**
H.S. graduate/GED
More than H.S.
Don’t know

7

38.8

8

44.4

3

16.7

5

18.5

8

29.6 14

51.9

16
10

57.1
50.0

7
5

25.0
25.0

5
5

17.9
25.0

4
9

33.3
34.6

6
12
1

50.0
46.2
3.7

2
5

16.7
19.2

8
15
9

57.1
57.7
45.0

5
4
9

35.7
15.4
45.0

1 7.1
7 26.9
2 10.0

4
8
3

21.1
44.4
15.0

8
4
12

42.1
22.2
60.0

7
6
5

36.8
33.3
25.0

Yes
No

20
13

40.0
81.3

17
3

34.0 13 26.0
18.8 0 0.0

11
7

24.4
33.3

21
6

46.7 13
28.6 8

28.9
38.1

History of illegal injection drug
useb
Yes
No

16
15

55.2
50.0

7
11

24.1
36.7

9
7

32.1
26.9

9
11

32.1 10
42.3 8

35.7
30.8

Gender

Education

Poverty indexa
< 1.0 (below poverty)
1.0-1.9 (near poverty)
2.0+ (above poverty)
Have health insurance

6 20.7
4 13.3

* = P value < 0.05 for chi-square test of difference for comparison of each racial/ethnic group between time
periods 2005-2008 and 2009-2012 (Fisher’s exact test used for small cell sizes).
** = Includes 12th grade with no diploma
a = 2005-2008: n = 60 (6 missing data); 2009-2012: n = 57 (9 missing data).
b = 2005-2008: n = 59 (7 missing data); 2009-2012: n = 54 (12 missing data).
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Inferential Statistics
NCHS analytic guidelines state that data from the Hepatitis C Follow-Up
Questionnaire (HCQ) should not be used with sample weights to make national estimates
because of small sample size and a response rate below 50% (Centers for Disease Control
and Prevention, 2012d). Therefore, analyses were conducted in SPSS 21.0 using chisquare and, where appropriate (i.e. small cell sizes), Fisher’s exact tests. Percentages
reported are percent of respondents, not population estimates. Results were considered
statistically significant at the 0.05 level.
For Research Question 1, the variables of interest were three of the HCV-positive
participants’ responses from the Hepatitis C Follow-Up Questionnaire (HCQ). For
Research Question 2, the variables of interest were seven of the HCV-positive
participants’ responses from the HCQ. For both Research Questions 1 and 2, HCVpositive participants were defined as those who took the screening hepatitis C anti-HCV
test from the NHANES medical examination component, had a positive result, were
mailed a Review of Findings letter, and completed the HCQ. For both Research
Questions 1 and 2, the participants were categorized into three racial/ethnic groups
(Caucasian, African American, Hispanic/Other) and compared between two time periods,
2005-2008 and 2009-2012. In order to determine the independent relationship between
the 10 HCQ responses of all participants and each racial/ethnic group in two time periods,
the study analysis included logistic regression after controlling for the covariates of age,
gender, race/ethnicity, education, poverty index, health insurance status, and history of
illegal injection drug use.
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Results for Research Question 1
Research Question 1 was: Has the seeking of health care by HCV-positive
African Americans improved since 2008 following the introduction of new treatment
options as compared to other HCV-positive racial/ethnic groups? For Research Question
1, a chi-square test of difference, or Fisher’s exact test for small cell sizes, was conducted
for each racial/ethnic group’s health care seeking responses between two time periods,
2005-2008 and 2009-2012 (Table 6). The results demonstrated no statistically significant
difference of each racial/ethnic group’s health care seeking responses between the two
time periods.
Results for Research Question 2
Research Question 2 was: Has the response from health care providers to HCVpositive African Americans improved since 2008 following the introduction of new
treatment options as compared to other HCV-positive racial/ethnic groups? For Research
Question 2, a chi-square test of difference, or Fisher’s exact test for small cell sizes, was
conducted for each racial/ethnic group’s health care provider responses between two time
periods, 2005-2008 and 2009-2012 (Table 6). The results demonstrated no statistically
significant difference of each racial/ethnic group’s health care provider responses
between the two time periods.
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Table 6
Influence of Race/Ethnicity on Participants’ Responses, NHANES Hepatitis C Follow-Up
Questionnaire, Time Periods 2005-2008 and 2009-2012*

Racial/Ethnic group
Health care seeking responses
I saw a doctor about
the hepatitis C test resulta

Cauc

2005-2008
sample
AA
H/O

Cauc

2009-2012
sample
AA

N %

N

N

N

%

N

%

%

22 81.5

H/O
N

%

27 81.8

15 75.0

11 84.6

I have an appointment
to see a doctor about
the hepatitis C test result

1 16.7

1 20.0

1 50.0

0

0.0

0

0.0

0
1

0.0

I decided not to get treated because:
Side effects are unpleasant
Need to self-inject medicine
Too expensive
Hope of better future treatments
Some other reason given

4
2
5
3
5

50.0
28.6
71.4
2.9
62.5

1 50.0
0 0.0
0 0.0
0 0.0
3 100.0

1 50.0
0 0.0
1 50.0
0 0.0
1 50.0

3
3
4
1
4

50.0
60.0
66.7
20.0
66.7

1
1
1
1
2

33.3
33.3
33.3
33.3
50.0

1
3
0
1
2

20.0
60.0
0.0
20.0
40.0

Health care provider responses
Doctor did other blood tests
to check the liver
Don’t know

24 88.9
2 7.4

15 100.0
0 0.0

10 90.9
0 0.0

15 100.0
0 0.0

18 85.7
0 0.0

14 82.4
0 0.0

Doctor told me I have hepatitis C and:
I need regular medical follow-up
I do not need to worry about it
Other
Don’t know

16 59.3
7 25.9
3 11.1
1 3.7

8 53.3
6 40.0
0 0.0
1 6.7

4 40.0
5 50.0
1 10.0
0 0.0

9 60.0
0 0.0
5 33.3
1 6.7

8 38.1
8 38.1
5 23.8
0 0.0

10 58.8
4 23.5
3 17.6
0 0.0

I had a liver biopsy

10 50.0

6 66.7

Doctor advised me about meds
used to treat hepatitis C
(such as Interferon and Ribavirin)

17 85.0

8 88.9

Doctor advised me I should be treated

13 76.5

5

I was treated with the medications

9 52.9

4

Doctor told me I should not
be treated because:
Liver enzymes are normal
Do not have liver disease
Don’t need to do anything
Wait to be treated at a later time
No reason specified

2 50.0
0 0.0
0 0.0
0 0.0
1 25.0

4 66.7

15 83.3

%

17 81.0

8 53.3

9 69.2

7 53.8

5 83.3

13 86.7

13 100.0

11 91.7

62.5

4 80.0

10 76.9

9 69.2

8 66.7

57.1

3 60.0

6 46.2

8 66.7

7 58.3

0
0.0
0
0.0
0
0.0
2 100.0
0
0.0

1 100.0
0 0.0
0 0.0
0 0.0
0 0.0

1
1
1
1
1

1 50.0
1 50.0
0 0.0
2 100.0
0 0.0

1
1
0
1
1

33.3
33.3
33.3
33.3
33.3

* = Total and percentage are “within race” categories; missing data values were not included in the
calculations – only valid responses.
a = test result is defined as either the participant’s first positive hepatitis C test result or the NHANES
positive hepatitis C result.

25.0
25.0
0.0
25.0
25.0
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Table 7 reports the frequencies and percentages for both health care seeking and
health care provider HCQ responses of all participants in two time periods, 2005-2008
and 2009-2012. Missing data values were not included in the calculations, only valid
responses defined as “yes” or “no” to the HCQ questions. Using chi-square test of
difference, or Fisher’s exact test for small cell sizes, between the two time periods, the
results demonstrated no statistically significant difference of participants’ responses
between the two time periods. Within each time period (2005-2008 and 2009-2012) most
participants had reported that they had seen a doctor about their hepatitis C result (80.3%
and 81.8%, respectively) (Table 7). Of the participants within each time period (20052008 and 2009-2012) who had already seen a doctor, just over half (53.8% and 50.9%,
respectively) reported they were told that they had hepatitis C and needed a regular
medical follow-up. Approximately 60% of participants within each time period (20052008 and 2009-2012) reported having had a liver biopsy. Approximately 70% of
participants within each time period (2005-2008 and 2009-2012) reported being advised
by the doctor that they should be treated with medications. Just over one-half of the
participants within both time periods (2005-2008 and 2009-2012) reported that they
decided not to get treated because the treatment was too expensive (54.5% and 57.1%,
respectively).
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Table 7
Participants’ Responses, NHANES Hepatitis C Follow-Up Questionnaire, Time Periods
2005-2008 and 2009-2012*
2005 – 2008
Sample
N
%

2009 – 2012
Sample
N
%

53

80.3

54

81.8

NS

3

23.1

0

0.0

NS

6
2
6
3
9

50.0
18.2
54.5
27.3
69.2

5
4
8
3
8

35.7
30.8
57.1
23.1
53.3

NS

49
2

92.5
3.8

47
1

88.7
1.9

NS

28
18
4
2
20

53.8
34.6
7.7
3.8
57.1

27
12
13
1
24

50.9
22.6
24.5
1.9
58.5

NS
NS

30
22
16

85.7
73.3
55.2

37
27
21

92.5
71.1
56.8

NS
NS
NS

3
0
0
2
1

42.9
0.0
0.0
33.3
14.3

3
3
1
4
2

33.3
33.3
11.1
44.4
22.2

NS

P Value**

Health Care Seeking Responses
I saw a doctor
about the hepatitis C test resulta
I have an appointment to see a doctor
about the hepatitis C test result
I decided not to get treated because:
Side effects are unpleasant
Need to self-inject medicine
Too expensive
Hope of better future treatments
Some other reason given
Health Care Provider Responses
Doctor did other blood tests to check the liver
Don’t know
Doctor told me I have hepatitis C and:
I need regular medical follow-up
I do not need to worry about it
Other
Don’t know
I had a liver biopsy
Doctor advised me about medications
used to treat hepatitis C
(such as Interferon and Ribavirin)
Doctor advised me I should be treated
I was treated with the medications
Doctor told me I should not be treated because:
Liver enzymes are normal
Do not have liver disease
Don’t need to do anything
Wait to be treated at a later time
No reason specified

* = missing data values were not included in the calculation - only valid responses.
** = P value for chi-square test of difference between time periods 2005-2008 and 20092012. (Fisher’s exact test used for small cell sizes).
NS = not significant.
a = test result is defined as either the participant’s first positive hepatitis C test result or
the NHANES positive hepatitis C result.
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Logistic Regression Results
Logistic regression was conducted to examine HCQ responses of all participants
and each racial/ethnic group (Caucasian, African American, Hispanic/Other) within two
4-year time periods (2005-2008 and 2009-2012), and as a pooled analysis for the total 8year time period of 2005 to 2012 while controlling for the covariates of age, gender,
race/ethnicity, education, poverty index, health insurance status, and history of illegal
injection drug use.
2005 to 2008 time period. Table 8 contains the results from the logistic
regression analysis for the 2005 to 2008 4-year time period for HCQ participants who
saw a doctor about their test result. The model wald chi-square was significant, X2(1) =
4.018, p <0.05. This result indicated a statistically significant association between
having health insurance and seeing a doctor about the test result. The odds ratio of
537.33 (95% CI: 1.150 to 251113.35) showed that participants who had health insurance
were 537.33 times more likely than those who did not have health insurance to see a
doctor about their HCV-positive test result.
Table 8
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor
About the Test Result—2005-2008
Predictor

n

Wald
X2

Df

p

OR

95% CI
Lower

I have health insurance

54

4.018

1

<0.05

537.33

Upper

1.150 251113.35

Table 9 contains the results from the logistic regression analysis for the 2005 to
2008 4-year time period for HCQ participants who had a liver biopsy. The model wald
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chi-square was significant, X2(1) = 5.009, p <0.05. This result indicated a statistically
significant association between having health insurance and having had a liver biopsy.
The odds ratio of 76.67 (95% CI: 1.715 to 3427.80) showed that participants who had
health insurance were 76.67 times more likely than those who did not have health
insurance to have had a liver biopsy.
Table 9
Logistic Regression: Having Health Insurance Predicting Having Had a Liver Biopsy—
2005-2008
Predictor

I have had a liver biopsy

n

27

Wald
X2
5.009

df

1

p

<0.05

OR

76.67

95% CI
Lower

Upper

1.715

3427.80

2009 to 2012 time period. Table 10 contains the results from the logistic
regression analysis for the 2009 to 2012 4-year time period for HCQ participants who
saw a doctor about their test result. The model wald chi-square was significant, X2(1) =
5.065, p <0.05. This result indicated a statistically significant association between
having health insurance and seeing a doctor about the test result. The odds ratio of 12.50
(95% CI: 1.39 to 112.69) showed that participants who had health insurance were 12.5
times more likely than those who did not have health insurance to see a doctor about their
HCV-positive test result.
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Table 10
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test
Result—2009-2012
Predictor

I have health insurance

n

48

Wald
X2
5.065

df

1

p

< 0.05

OR

12.50

95% CI
Lower

Upper

1.39

112.69

2005 to 2012 time period. Table 11 contains the results from the logistic
regression analysis for the 2005 to 2012 8-year time period for HCQ participants who
saw a doctor about their test result. The model wald chi-square was significant, X2(1) =
1.332, p <0.05. This result indicated a statistically significant association between
having health insurance and seeing a doctor about the test result. The odds ratio of 12.32
(95% CI: 2.99 to 50.80) showed that participants who had health insurance were 12.32
times more likely than those who did not have health insurance to see a doctor about their
HCV-positive test result.
Table 11
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test
Result—2005-2012
Predictor

I have health insurance

n

102

Wald
X2
1.332

df

1

p

<0.05

OR

12.32

95% CI
Lower

Upper

2.99

50.80

Table 12 contains the results from the logistic regression analysis for the 2005 to
2012 8-year time period for HCQ participants who have had a liver biopsy. The model
wald chi-square was significant, X2(1) = 6.942, p <0.05. This result indicated a
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statistically significant association between having health insurance and having had a
liver biopsy. The odds ratio of 12.69 (95% CI: 1.92 to 84.02) showed that participants
who had health insurance were 12.69 times more likely than those who did not have
health insurance to have had a liver biopsy.
Table 12
Logistic Regression: Having Health Insurance Predicting Having Had a Liver Biopsy—
2005-2012
Predictor

I have health insurance

n

56

Wald
X2
6.942

df

1

p

<0.05

OR

12.69

95% CI
Lower

Upper

1.92

84.02

Table 13 contains the results from the logistic regression analysis for the 2005 to
2012 8-year time period for Caucasian HCQ participants who saw a doctor about their
test result. The model wald chi-square was significant, X2(1) = 3.84, p = 0.05. This
result indicated a statistically significant association between having health insurance and
seeing a doctor about the test result. The odds ratio of 21.53 (95% CI: 1.00 to 463.81)
showed that Caucasian participants who had health insurance were 12.32 times more
likely than those who did not have health insurance to see a doctor about their HCVpositive test result.
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Table 13
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test
Result for Caucasian Ethnicity—2005-2012
Predictor

I have health insurance

N

43

Wald
X2
3.84

df

1

p

0.05

OR

21.53

95% CI
Lower
1.00

Upper
463.81

Table 14 contains the results from the logistic regression analysis for the 2005 to
2012 8-year time period for African American HCQ participants who saw a doctor about
their test result. The model wald chi-square was significant, X2(1) = 3.83, p = 0.05. This
result indicated a statistically significant association between having health insurance and
seeing a doctor about the test result. The odds ratio of 59.96 (95% CI: .99 to 3263.77)
showed that African American participants who had health insurance were 59.96 times
more likely than those who did not have health insurance to see a doctor about their
HCV-positive test result.
Table 14
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test
Result for African American Ethnicity—2005-2012
Predictor

I have health insurance

n

35

Wald
X2
3.83

df

1

p

0.05

OR

56.96

95% CI
Lower

Upper

.99

3263.77

Based on the result of the data analyses used in this study, both stated null
hypotheses were not rejected and it was concluded that there were no statistically
significant associations between the health care seeking behavior and responses from
health care providers for HCV-positive African Americans before (2005-2008) and after
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(2009-2012) the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups. When controlling for the covariates of age, gender,
race/ethnicity, education, poverty index, health insurance status, and history of illegal
injection drug use, logistic regression did reveal that having health insurance was a
significant determinant of being likely to see a doctor for the HCV-positive test result for
all participants in both the 4-year time periods (2005-2008 and 2009-2012), as well as all
participants, Caucasians, and African Americans as an 8-year pooled analysis (2005 to
2012). Additionally, the results revealed that having health insurance was a significant
determinant of having had a liver biopsy for all participants in the 4-year time period of
2005 to 2008, and all participants in the 8-year pooled analysis (2005 to 2012). The
logistic regression did not identify any other results of statistical significance with all
participants or each racial/ethnic group in both time periods (2005-2008 and 2009-2012)
and as a pooled analysis (2005-2012).
Summary
In conclusion, the findings of this study do not support the hypotheses that there is
a statistically significant relationship between the health care seeking behavior and
provider responses of HCV-positive African Americans before (2005-2008) and after
(2009-2012) the introduction of new treatment options as compared to other HCVpositive racial/ethnic groups within the framework of the theory of planned behavior and
theory of reasoned action model. In Chapter 5, I will interpret these results in the context
of the current theories and understanding of HCV-positive African Americans and
potential risk factors. Further, I will present limitations of the study and a summary of
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findings. Recommendations for further research as well as the potential impact these
findings may have on social change will be also be discussed in Chapter 5.
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Chapter 5: Discussion
Introduction
The hepatitis C virus (HCV) is a major cause of liver disease, hepatocellular
carcinoma, and end stage liver disease in the United States (Centers for Disease Control
and Prevention, 2012a). As previously discussed, African Americans represent only 13%
of the U.S. population, but make up the largest racial group (22%) out of the 3.5 million
persons infected with chronic HCV. Disparities in access to care and treatment include a
complex set of individual, interpersonal, socioeconomic, and environmental factors that
influence the course of HCV infection in the African American population, resulting in
poorer outcomes and survival.
This research study used quantitative data from the 2005-2012 NHANES datasets.
The purpose of this study was to determine whether the seeking of health care by HCVpositive African Americans and the responses from health care providers to HCVpositive African Americans have improved since 2008 following the introduction of new
treatment options, as compared to other HCV-positive racial/ethnic groups. To date, no
published studies were found concerning the relationship between the seeking of health
care and provider responses for HCV-positive African Americans before and after the
introduction of new treatment options.
Based on the results from the chi-square test of difference and logistic regression
analyses conducted for hypothesis testing, I failed to reject the null hypotheses for my
two research questions. It was determined that the health care seeking behavior and
health care provider responses for HCV-positive African Americans had not improved as
of 2008 with the introduction of new treatment options, as compared to other HCV-
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positive racial/ethnic groups. The results from the logistic regression revealed that all
participants in both of the 4-year time periods studied (2005-2008 and 2009-2012) who
had health insurance were more likely to see a doctor for their HCV-positive test result.
These same results were also found in the 8-year pooled analysis (2005-2012) with all
participants, Caucasians, and African Americans. Additionally, the results revealed that
all participants in the 4-year time period of 2005 to 2008, and all participants in the 8year pooled analysis (2005-2012) who had health insurance were more likely to have had
a liver biopsy.
Interpretation of the Findings
Overall, the findings of this study indicated that there had not been any
improvement in the health care seeking behavior and provider responses for HCVpositive African Americans or other HCV-positive racial/ethnic groups since 2008 with
the introduction of newer treatment options. Participants in the 2005-2008 time period
were more likely to be younger than age 50 (p < 0.05) and Caucasian (p < 0.05) as
compared to participants in the 2009-2012 time period. In comparing each of the
racial/ethnic groups between the two time periods, the Hispanic/Other group in the 20052008 time period was more likely to be younger than 50 years of age (p < 0.05) as
compared to the Hispanic/Other group in the 2009-2012 time period. A statistically
significant relationship did not exist with each of the racial/ethnic group’s (Caucasian,
African American, Hispanic/Other) responses to the Hepatitis C Follow-Up
Questionnaire (HCQ) between two time periods (2005-2008 and 2009-2012). Eighty-one
percent of the study sample reported that they had seen a doctor about their past or
current HCV infection, with 51% having reported being told that they had hepatitis C and

93
needed a regular medical checkup. Although approximately 70% of all participants were
told that they should be treated with medications, of those who had decided not to get
treated, 58% had reported that this was because the treatment was too expensive.
With the inclusion of sociodemographic covariates in the regression models,
results indicated significant associations with participants who had health insurance.
Having health insurance, while controlling for other variables, was significantly
associated with the HCQ response of “I have seen a doctor about my test result”. This
was evident in all participants in both time periods (2005-2008 and 2009-2012), and as a
pooled analysis (2005-2012) with all participants, and both Caucasian and African
American racial/ethnic groups. In addition, having health insurance, while controlling for
other variables, was significantly associated with the HCQ response of “I had a liver
biopsy”. This was evident in all participants in both the 2005 to 2008 4-year time period,
and as an 8-year pooled analysis (2005-2012). A total of 72% of the study sample had
health insurance, with 58% reporting having had a liver biopsy; and, as previously
discussed, 81% of the study sample reported having seen a doctor about their past or
current HCV infection.
These findings are consistent with those of researchers who examined the impact
of having health insurance coverage. Turner et al. (2013) surveyed 600 injection drug
users in New York City and found that African Americans were less likely to have visited
a private medical office in the past year, whereas those with higher income and health
insurance coverage were more likely to visit a private medical office. Melia et al. (2011)
found that HCV-positive African Americans are disproportionately affected by lack of
adequate health insurance and high treatment costs. Gordon et al. (2015) found that
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having private health insurance coverage was associated with lower odds of cirrhosis in
hepatitis C patients.
Limitations of the Study
There were several limitations to this study. The NHANES survey is crosssectional by design. Limitations of using successive cross-sectional survey data over
time include: (a) reliance on the continuity of the data, (b) inability to establish individual
change, and c) inability to determine a causal relationship (King-Hele, 2005). As
NHANES data were collected at one point in time, longitudinal trends in health behavior
cannot be examined. Selection bias and sampling bias may be limitations of the study;
however, the NHANES survey uses a complex, stratified, multistage probability
sampling procedure to minimize this potential risk (Centers for Disease Control and
Prevention, 2013a). Although the Hepatitis C Follow-Up Questionnaire (HCQ) is nested
within the NHANES, the data from the HCQ cannot be used to generate population
estimates because of the small number of respondents and low response rate.
Frequencies for some questions may be affected by differences in characteristics of HCQ
participants versus nonparticipants. In addition, the small sample size limited the power
to detect statistically significant differences between subgroups. Lastly, as the data are
self-reported, another limitation is the usual biases associated with such data (e.g., recall
bias and/or information bias), including the possibility of participants not understanding
questions regarding medical information, such as whether they had a particular medical
procedure or blood test performed or what they had been told by a health care provider.
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Recommendations
This study reported results for a sample of NHANES participants who responded
to a follow-up questionnaire after having tested positive for past or current HCV infection
from 2005 through 2012, which, to my knowledge, is the only questionnaire of such
individuals to be conducted as part of a national population-based study. Overall, the
study did not find any significant improvements in the health care seeking behavior or
provider responses for HCV-positive African Americans since 2008 after the introduction
of new treatment options as compared to other HCV-positive racial/ethnic groups. The
landscape and discovery of new and improved direct-acting antivirals (DAAs) to treat
HCV infection are continuing to evolve into regimens with shorter durations, better
tolerability, and higher cure rates. During the time period in which the first-generation
DAAs were available and being used to treat HCV-infected individuals, there already
existed ongoing studies of second-generation DAAs that demonstrated even better
tolerability and efficacy. In these studies, even higher rates of sustained viral response or
cure (89%-90%) have been demonstrated in treatment-naïve patients as compared to firstgeneration agents (Kohli, Shaffer, Sherman, & Kottilil, 2014). In addition, one study
conducted in 2013 found that 90% of physicians in the United States reported that they
were “warehousing” patients (holding off treatment) in expectation of more efficacious
and tolerable new therapies (Taylor, 2013). As of 2015, there is currently a total of six
second-generation DAAs that have been approved and are being used (alone or in
combination) for the treatment of HCV infection (U.S. Food and Drug Administration,
2014). With second-generation DAAs providing improvements in efficacy and
tolerability across all racial/ethnic groups, further research might focus on the HCV-
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infected population as a whole to determine whether differences exist in health care
seeking behavior and provider responses as compared to the first-generation DAAs.
Additional research may also be needed to evaluate strategies to enhance assessment,
adherence, and treatment responses among those at risk, including special populations,
particularly as new treatments for HCV infection continue to become available.
Due to the close association between a person having health insurance coverage
and seeing a doctor and/or having a liver biopsy, future research efforts might focus on a
closer examination of health insurance status as a predictor for seeking medical care
and/or getting medical procedures in different clinical settings. In addition, over one-half
of the study participants who decided not to get treated with medications reported that it
was because the HCV treatment was too expensive. Obamacare’s individual mandate
required most Americans to obtain health insurance by January 1, 2014
(obamacareusa.org, 2015). Future research might also examine the potential association
that health insurance coverage has on the screening and preventive care efforts for
hepatitis C, as well as treatment and outcomes.
Implications for Social Change
These research findings suggest that more intensive efforts are needed to identify
and test those at risk for HCV infection and the need to educate patients and providers
about appropriate interaction on prevention decisions and actions. Prior to this study, no
previously published study had compared the health care seeking behavior and provider
responses of HCV-positive African Americans before the introduction of new treatment
options (2005-2008) and after the introduction of new treatment options (2009-2012) as
compared to other HCV-positive racial/ethnic groups. HCV infection remains a critical
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public health challenge in the African American population. African Americans are most
at risk for infection and transmission due to illegal injection drug use behavior, in
addition to worse health outcomes to include increased morbidity and mortality. Positive
social change may happen by emphasizing the awareness of the risks of HCV infection,
reducing provider bias, removing barriers to care, and introducing resources into the
African American and underserved communities; as a result, there may be improvements
in screening, treatment, and outcomes. The findings of this study may aid public health
professionals in the design of public health policies, educational programs, and screening
and treatment recommendations that could lead to positive social change among the
groups most at risk for hepatitis C infection.
Prevention is the key to reducing the risk of HCV transmission. The findings of
this study may impact change socially by increasing public communication within the
African American communities which would raise awareness of the risks of HCV
infection; as well as the potential implementation of local neighborhood-level clinics,
syringe exchange programs, and additional resources in the lower and poor communities
to improve access to health care and outcomes for this afflicted population.
Conclusion
To my knowledge, this study was the first study to explore the association
between the health care seeking behavior and provider responses for HCV-positive
African Americans before and after the introduction of new treatment options as
compared to other HCV-positive racial/ethnic groups. Results from the study did not
identify a statistically significant relationship of health care seeking behavior and
provider responses between the two time periods. With regard to analyzing the

98
covariates, the study did identify a significant association between having health
insurance coverage and seeing a doctor about the HCV test result and/or having a liver
biopsy. The findings from this study add to the body of knowledge by quantifying the
association between the health care seeking behavior and provider responses over an 8year period collectively and within each racial/ethnic group (Caucasian, African
American, Hispanic/Other).
There have been numerous approaches to prevention and intervention of HCV
infection. The identification, counseling, and testing of persons at risk should be a top
priority. The National Prevention Information Network provides persons and health care
professionals with the most current information, resources, and tools to support your
organization’s efforts to prevent viral hepatitis; as well as links to find hepatitis C
providers/clinics in a specific area for networking, and access to federal and private
funding opportunities (Centers for Disease Control and Prevention, 2012). All of these
resources can be beneficial to educate the healthcare professional on persons at risk for
HCV, and who should be screened, plus access to patient-centric educational resources.
For the African American population, increasing awareness and knowledge
among health care providers and communities about hepatitis C infection, and improving
access to quality prevention, research trials, care, and treatment services, while
eliminating disparities is essential. With the landscape and discovery of new and
improved drugs to treat HCV infection continuing to evolve into regimens with shorter
durations, better tolerability, and higher cure rates, the findings of this study lay the
groundwork for researchers to comparatively assess any improvement or changes in
health care seeking behavior and provider responses by HCV-infected populations
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moving forward. The results of this study do not support the hypotheses that the health
care seeking behavior and health care provider responses for HCV-positive African
Americans has improved as of 2008 with the introduction of new treatment options, as
compared to other HCV-positive racial/ethnic groups.
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